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Abstract
Development of perfluorocarbon nanoemulsions for delivery of therapeutic
nucleic acids
Ling Ding
University of Nebraska Medical Center, 2021
Supervisor: David Oupický, Ph.D.
Local pulmonary administration of therapeutic siRNA represents a promising approach
to the treatment of lung fibrosis, which is currently hampered by inefficient delivery.
Pancreatic cancer (PC) is a fatal human cancer whose progression is highly dependent
on the nervous tumor microenvironment. siRNA delivery has been well studied as a
promising therapeutic agent for several disease, including the pulmonary fibrosis and
cancer. Perfluorocarbon nanoemulsions have been studied in the treatment of various
diseases as drug delivery systems. We report development of perfluorooctylbromide
(PFOB) nanoemulsions as a platform to facilitate delivery and penetration of a therapeutic
siRNA to pulmonary fibrosis lung and orthotopic pancreatic tumors. PCX@PFOB
emulsion, which contained the polymeric CXCR4 antagonist PCX with PFOB, is a dual
functional emulsion to inhibit CXCR4 and deliver siRNA. This dissertation hypothesized
that inhibition of CXCR4 by PCX@PFOB emulsion combined with siRNA delivery
cooperatively enhances the pulmonary fibrosis and PC treatment.

In chapter 1, an overview of pulmonary siRNA delivery and the recent progress and
challenges are given, together with introduction to PC.
Chapter 2 describes PAMD@PFOB/siRNA emulsion polyplexes (EPs) combined with
CXCR4 inhibition and STAT3 silencing. We proposed that the EPs overcome two major
pulmonary siRNA delivery barriers: cell membrane and mucus layer. The results show
that the EPs are capable of efficiently silencing the expression of STAT3 and inhibiting
chemokine receptor CXCR4 – two validated targets in pulmonary fibrosis. Both in vitro
and in vivo results demonstrate that the nanoemulsions improve mucus penetration and
facilitate effective cellular delivery of siRNA. Pulmonary treatment of mice with bleomycininduced pulmonary fibrosis showed strong inhibition of the progression of the disease and
significant prolongation of animal survival.
Chapter 3 explores P@P EPs to target the tumor-neuronal interaction for PC treatment
via NGF silencing by EPR-independent delivery of nanoparticles. P@P EPs exhibited
deep tumor penetration that was dependent on exocytosis, and enhanced NGF gene
silencing in vitro and in vivo when compared with control polycation/siRNA polyplexes,
leading to the effective and safe suppression of tumor growth in orthotopic pancreatic
cancer.
In Chapter 4, conclusion and future directions are described.
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Chapter 1. Introduction
1. Pulmonary siRNA delivery for lung disease: Review of recent progress and
challenges
Please note that this part of the dissertation was published in the Journal of Controlled
Release (Ling Ding et al, 2020). As the first author, I wrote this review. Prof. Oupicky, Prof.
Knoell, Prof. Wyatt, and Siyuan Tang helped with editing the manuscript. All the co-authors
agree with including their work in this dissertation.
Lung diseases are a significant global public health problem creating a large
economic burden [1]. Because the lung directly interfaces with the external environment,
inhaled drug delivery to therapeutically address pulmonary diseases has been a
longstanding goal. In addition to endogenous stimuli, the lungs are susceptible to
inhalation injury and multiple related diseases as an organ exposed directly to harmful
substances [2-4]. Pulmonary delivery offers the potential to address unmet medical needs
in lung-related disease including allergy [5], asthma [6], idiopathic pulmonary fibrosis (IPF)
[7], cystic fibrosis (CF) [8], both viral and bacterial infections [9], acute lung injury (ALI)
[10], chronic obstructive lung disease (COPD) [11], and lung cancer [12].
Inhalation-based delivery of small interfering RNA (siRNA) designed for efficient,
targeted delivery to specific cells within the lungs holds great promise but remains yet to
be realized. In general, inhalation drug delivery systems, if designed effectively, reduce
the overall dose required to treat pulmonary disorders in comparison to oral or parenteral
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delivery systems. They also avoid first-pass metabolism, reducing dose and risk of toxicity
from metabolic byproducts. It provides a reproducible and possibly more economical
platform that can be provided to diverse patient populations within a variety of settings and
on a daily basis if necessary. The now commonly used dry powder inhalation (DPI) devices
used to treat asthma or COPD serve as excellent examples [13].
Active targeting of the lung using siRNA has been a postulated approach for a variety
of lung diseases. siRNAs induce gene silencing by a sequence-specific posttranscriptional
process known as RNA interference (RNAi) [14]. With the first siRNA medication (Patisiran)
approved in the USA and EU [15], the field of siRNA delivery received a strong stimulus
to expand the scope of RNAi therapeutics to other diseases [16]. Patisiran is a
nanoparticle formulation containing a chemically modified siRNA encapsulated with lipid
excipients for delivery to hepatocytes. The lipid nanoparticles are composed of ionizable
cationic lipids (DLin-MC3-DMA), phospholipid (DSPC), cholesterol, and polyethylene
glycol modified lipids (PEG2000-C-DMG), that are combined via rapid mixing under acidic
conditions. The siRNA is modified with eleven 2’-methoxy-modified sugar residues and
four 2’-deoxythymidine residues to improve the stability and to avoid off-target effects [17].
Another RNAi drug GIVLAARI™ (givosiran) was approved in November 2019 for the
treatment of acute hepatic porphyria (AHP) [18]. The treatments based on siRNA provide
potential benefits compared to traditional drugs, including target specificity and ability to
inhibit the expression of mutant proteins without affecting wild type ones [16]. For RNAibased therapies, a suitable delivery strategy is critical for optimum therapeutic effect. In
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many diseases like cancer, amyloidosis, viral infections, hypercholesterolemia, and acute
kidney injury (AKI), systemic delivery is necessary for siRNA to reach a specific target.
There are more than 25 systemically administered siRNA drug candidates are under
clinical trials [19, 20]. However, systemic delivery of therapeutic siRNA targeting tissues
other than the liver has proven challenging. Local delivery of siRNA provides potentially
better gene silencing at the target site and circumvents the first-pass effect thus resulting
in lower doses and reduced off-target effects [21]. There are thirteen clinical trials that
utilize local siRNA delivery as of the fall of 2020 [20]. Direct delivery of siRNA into the
lungs is non-invasive and allows for self-medication [22]. Addressing pulmonary delivery
barriers and intracellular delivery of siRNA is critical for success of pulmonary siRNA
delivery. The use of nanoparticles to deliver siRNA can help to overcome anatomical
barriers, mucociliary clearance (MCC), intracellular siRNA uptake limitations, and
macrophage alveolar clearance. For optimum siRNA pulmonary delivery, siRNAs need to
be deposited to the target region of the lungs and released at the target cells. An ideal
siRNA delivery system should: (1) condense siRNA into a stable particle, (2) protect siRNA
from nuclease degradation, (3) improve cellular uptake and promote endosomal escape
to release siRNA to the cytoplasm of target cells, and (4) specifically silence the target
gene with low off-target effects and toxicity [3]. In this review, we highlight the progress of
pulmonary siRNA delivery over the past decade.

4
1.1.

Pulmonary barriers that affect siRNA delivery

Efficient delivery of siRNA directly to the lungs with the intent to treat lung diseases
is relatively complex despite the convenience of established inhalation delivery strategies.
Depending on the desired location of delivery for a given disease state (upper airway,
lower airway, alveolar region, systemic absorption) a number of considerations that
include packaging, particle size, morphology, geometry, surface properties, cell target,
and host defense mechanisms must be taken into consideration. There are three
mechanisms of drug deposition in the respiratory system: impaction, sedimentation, and
diffusion. From a particle point of view, if the intended location of drug deposition is the
alveolar region, it will require navigation past 23 branching segments [23]. Therefore, the
formulation must be designed with an optimal aerodynamic particle size that can be
maintained and afford deep penetration into the lung. In particular, large particles with
aerodynamic diameters greater than 6 μm deposit on the back of the larynx in the upper
airways, never reaching the lower airway. If the intent is to deliver siRNA to the bronchiolar
or alveolar region, then smaller particles are required. Likewise, if particles are designed
with an aerodynamic diameter less than 1 μm they are predominantly exhaled due to
Brownian motion, never achieving deposition [24, 25]. Accordingly, the optimal
aerodynamic diameter for efficient lung deposition typically is in a range between 1-5 μm.
Considering that innate host barrier defense mechanisms are designed to keep
foreign particles out of the lungs, carefully consideration of these natural defense
mechanisms is necessary when formulating pulmonary siRNA therapeutics. Perhaps the
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biggest obstacle to particulate drug delivery is the mucociliary transport system, including
the mucociliary clearance and phagocytosis by macrophages. A variety of epithelial cell
subtypes forms a continuous barrier, sealed by tight junctions, that secrete mucus and
other host defense factors into the lumen that work in concert with oscillating ciliary
projections particularly in the upper airway and bronchiolar regions [26]. Together this
system works to capture foreign particles and escalate them up and out of the airway.
Further, excessive mucus production is a characteristic encountered in many
inflammatory-based lung diseases including, but not limited to, CF, chronic bronchitis and
asthma thereby potentially making it more difficult for a particle to avoid capture or to
traverse this barrier in order to reach intended target cells [27]. The deeper a particle
penetrates into the lung, the more frequently it will encounter alveolar macrophages that
are designed to phagocytose and destroy foreign particles, as this too may be modified
further in certain disease states (discussed in more detail later). Finally, the epithelial
barrier is bound together via multiple tight junctions designed to maintain a patent airway.
The epithelium is in a polarized state such that the expression of surface bound proteins
may be restricted to or predominantly expressed on the apical or basolateral surface, thus
making it more or less accessible for receptor-targeted approaches [28].
The pulmonary surfactant (PS) and macrophages in the airspace are another
obstacle to affect the pulmonary siRNA delivery. The alveolar macrophages are
phagocytes residing in the airspace that play a critical role in homeostasis, host defense
and tissue remodeling. In the following section, we will focus on the details of the most
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important pulmonary barriers to siRNA delivery and on how to strategically overcome the
barriers in order to improve siRNA delivery efficiency.
1.1.1.

Pulmonary surfactant (PS)

PS is a surface-active material covering the entire alveolar surface, which is secreted
by specialized alveolar type II epithelial cells (AEC II). The main physiological role of PS
is to maintain low surface tension upon expiration to prevent alveolar collapse. PS has
been extensively studied because of the functional role in mammalian breathing [29, 30].
Inhaled gene vectors that make it to the alveoli must retain their stability and function in
the presence of PS which are abundant in the airspace. Natural human PS has a complex
composition of ~8% of surfactant proteins and ~92% of lipids by mass. The protein part
consists of four surfactant proteins which can be structurally divided into two parts: the
larger hydrophilic SP-A and SP-D, and the smaller hydrophobic SP-B and SP-C [31]. The
hydrophilic surfactant proteins, also known as collectins, participate in the opsonization
process to promote pathogen and particle uptake by phagocytic cells [32]. The
hydrophobic surfactant proteins regulate the interfacial surfactant absorption dynamics,
which improve the lipid transfer and membrane fusion process. The lipid fraction mainly
contains zwitterionic phosphatidylcholine (~60-70 wt%), anionic phosphatidylglycerol (~10
wt%), and neutral lipids, of which cholesterol is the most abundant (~8-10 wt%) [29, 30].
From an inhalation therapy perspective, PS is primarily considered as one of the
extracellular barriers in the deep lung which needs to be overcome to gain access to the
underlying target cells [33, 34]. Poractant alfa, a modified PS from swine, and beractant,
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bovine PS, are commercially available for treating neonatal respiratory distress syndrome
[35].
1.1.2. Alveolar macrophages
Alveolar macrophages are phagocytes residing in the airspace that play a critical role
in homeostasis, host defense, and tissue remodeling. There are 12-14 macrophages in
each alveolus and the numbers may vary in pathological states, such as observed
increases in smokers [36]. Following inhalation, particles can be rapidly cleared by
alveolar macrophages via opsonin-independent scavenger receptors or by opsonindependent mechanisms, which trigger the release of pro-inflammatory cytokines TNF-α
and IL-1β and initiate the production of further inflammatory mediators, consequently
leading to the acute lung toxicity [37, 38]. In alveoli, phagocytosis by macrophages and
migration towards the mucociliary escalator contribute to the overall elimination. Although
macrophages are less efficient in the phagocytosis of nanoparticles than microparticles
[39, 40], siRNA-containing nanoparticles may aggregate in the presence of PS, which
increases their susceptibility to macrophage clearance. In the case of polymeric
nanoparticles, studies have shown that particles with hydrophobic surfaces are more
susceptible to phagocytosis by macrophages than those with hydrophilic surfaces [41].
The alveolar macrophages in the bronchoalveolar lumen play a critical role in lung
inflammatory pathologies and therefore constitute attractive target for siRNA therapeutics.
However, delivery of siRNA to macrophages presents a significant challenge, because the
fully differentiated alveolar macrophages are difficult to transfect. Several strategies have
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been devised to overcome this challenge. PLGA microparticles with encapsulated siRNA
were successfully aerosolized and resulted in strong macrophages transfection [42].
Macrophage uptake of anionic PLGA-lipid hybrid microparticles was greater than uptake
of positively and negatively charged precursor PLGA particles [43]. Lynn et al. developed
a hybrid core-shell nanoparticle that mediated efficient in vivo delivery of siRNA to alveolar
macrophages [44]. Duo et al. evaluated an inhaled exosomes to deliver siRNA to activate
or inhibit alveolar macrophages, which can modulate pulmonary immune response, and
results proved that only lung macrophages efficiently take up exosomes in vivo [45].
Despite the promising results, better understanding of how environmental damage affects
alveolar macrophage function is necessary for the development of macrophage-targeted
treatment strategies.
1.1.3. Mucociliary clearance (MCC) and periciliary layer (PCL)
MCC by ciliated epithelial cells serves as a barrier to pulmonary siRNA delivery. In
the upper and central airways, epithelial cell mucus is a defense barrier against irritants
such as bacteria, allergens, and other inhaled particles (Figure 1.1). Airway mucus is
produced by secretory cells including goblet cells and club cells and forms an adhesive
and hyper-viscoelastic barrier to impede particle deposition in the deeper lung [46, 47].
Airway mucus is composed of mucins, water, and other gel-like constituents [46]. Mucins
are glycoproteins with densely glycosylated and negatively charged regions. The mucus
covering the airway epithelium has been recognized as one of the greatest obstacles to
siRNA delivery. Electrostatic interactions with positively charged siRNA particles may trap
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the particles in the mucus layer resulting in increased MCC and decreased delivery
efficacy [48]. Demeester et al. showed that cationic DOTAP/DOPE lipoplexes were stable
when incubated with diluted CF sputum obtained from patients, but binding of mucins
decreased the transfection efficacy. Mucins, however, did not cause aggregation or
dissociation of the lipoplexes, indicating that mucins alter (intra)cellular steps in the
transfection process [49]. Nanoparticles trapped in the mucus layer of the airways are
cleared by MCC or cough-driven clearance. However, particles that rapidly penetrate
through the mucus layer and into the PCL may be retained significantly longer in the lungs.
The PCL is believed to be nearly stationary and presents a significantly steric barrier to
particle penetration. In CF lungs, dehydration of PCL mediated by dysregulation of
epithelial sodium channels in the airway epithelium can cause osmotically driven collapse
of the PCL, which makes the PCL mesh tighter and thus increases further the barrier to
particle transport. Overall, particles that can penetrate the mucus layer but not the PCL
would also be cleared via MCC or by macrophages [39].
Multiple strategies have been studied for effective mucus layer penetration and MCC
avoidance, including mucus-penetrating particles (MPPs). Unlike mucoadhesive particles,
which are trapped in the luminal mucus layer and eliminated by the MCC, MPPs diffuse
through mucus and avoid MCC. Surface properties of the MPPs are crucial in improving
mucus penetration [38, 46, 48, 50, 51]. To favor penetration, MPPs should be small
enough to avoid entrapment in the mucin mesh and have hydrophilic and neutral surface
charge to avoid interactions with the hydrophobic and negatively charged groups of
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mucins. However, siRNA delivery often relies on lipophilic and positively charged carriers
[46]. Therefore, careful surface engineering strategies are needed. Among those, dense
surface coating with polyethylene glycol (PEG) has been the most successful approach.
Surface PEG affects lung distribution, mucus penetration, and lung-residence time of the
siRNA particles [38, 50, 52]. Densely PEGylated DNA MPPs showed greatly enhanced
particle distribution, lung retention time, and gene transfer following intranasal
administration compared to similarly sized mucoadhesive nanoparticles [52]. A recently
reported alternative to PEG to facilitate mucus penetration relies on a unique combination
of lipophobic and hydrophobic properties of perfluoroalkyl polymers [51].
The use of adjuvants which can modulate the biological barriers is another suitable
approach to overcome the barriers. Adjustment of biological barriers with properly selected
adjuvants is one possible way to enhance the efficiency of pulmonary siRNA delivery.
However, it is important to ensure that any adjuvant approaches do not cause significant
toxicity or disrupt the normal lung function. The most widely explored method in this
context has been the use of mucolytic agents that degrade or loosen primary
macromolecular components of airway mucus, such as, the recombinant human DNase
(rhDNase, Pulmozyme®) and N-acetyl cysteine (NAC, Mucomyst®) [53], which can
significantly reduce the viscoelasticity of airway mucus. Both are clinically used in helping
CF patients clearing accumulated mucus from the airways. It has been reported that pretreatment with NAC increases mucus mesh spacing which leads to rapid diffusion and
improved penetration through airway mucus [54]. Improving airway surface hydration with

11

osmotically active inhaled hypertonic saline provides another effective way of mucus
clearance [55, 56]. Inhaled mannitol creates an osmotic drive for water to move into the
airway lumen. The consequent increased hydration of the airway surface decreases the
adherence of mucus to the epithelium, facilitates the coupling of mucus and cilia thereby
increasing mucus clearance. Inhaled dry powder mannitol (Bronchitol®) is promising to be
an effective treatment for the clearance of retained airway secretions in the patients with
CF and thereby may also be useful as an adjuvant to inhaled gene therapy [57].

Figure 1.1 Schematic illustration of the pulmonary barriers that affect siRNA delivery
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1.1.4. Cellular and intracellular barriers
To exert its therapeutic effect, siRNA must be delivered to the cytoplasm of the target
cells. The cell uptake pathway associated with the siRNA delivery by non-viral vectors is
endocytosis. There are four main mechanisms of endocytosis. First, clathrin-mediated
endocytosis, which is the most widely studied mechanism and is involved in receptormediated uptake of nanoparticles. For example, transferrin receptor, low density
lipoprotein receptor, and epidermal growth factor receptors have been explored to mediate
endocytic uptake. Second, caveolin-dependent endocytosis, which generates cytosolic
caveolar vesicles following nanoparticle binding to the cell membrane. Third,
macropinocytosis, which generates large macropinosomes containing extracellular fluid
and soluble proteins. Fourth, other endocytic mechanisms that rely on actin-driven
membrane protrusions, which subsequently fuse with and separates from the plasma
membrane to generate macropinosomes [58]. For the most obstructive lung diseases,
such as COPD and CF, airway epithelial cells are the primary target for treatment.
Unfortunately, these cells display low endocytic activity on the apical side [39]. Agents
such as the natural airway surfactant lysophosphatidylcholine (LPC) or the calcium
chelator EGTA were employed to transiently disrupt epithelial tight junctions and improve
vesicular stomatitis virus (VSVG)-HIV entry in vivo [59]. Particles smaller than 150 nm
allow for endocytosis and also limit macrophage uptake, both of which help to avoid lung
clearance [60]. Upon endosomal cellular entry, siRNA must escape from the endosomes
into the cytoplasm. Multiple strategies have been studied to overcome and promote the
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endosomal escape of siRNA that are directly applicable to pulmonary delivery [61-66].
Active targeting using ligand moieties that bind to over-expressed receptors on the surface
of target cells is a widely explored strategy to enhance cell uptake and to improve
therapeutic efficiency [67]. For example, T-cell targeted pulmonary siRNA delivery using
transferrin and melittin-PEI conjugate shows efficient uptake in active T cells and
endosomal escape for the treatment of asthma [68]. As cholesterol is an essential
component of the cell membrane and can be metabolized, it is often used as the lipid
anchor for improving stability and cellular uptake as well as decreasing the cytotoxicity of
the carriers [69]. Once taken up by the target cells, siRNA particles must overcome several
intracellular barriers, including but not limited to the endosomes and lysosomes. These
barriers are shared in numerous organs and tissues in addition to the lungs and have been
extensively reviewed elsewhere [70].
1.2.

Disease-dependent pathological changes and their role in pulmonary
disease and impact on siRNA delivery

When considering whether a patient with a given lung disease would benefit from
inhalation of siRNA there are a number of important host factors that should first be
determined. Pulmonary mechanics play a vital role in deciding whether medication can be
inhaled deep into the lung, retained, and made available to target cells. In the majority of
asthma or COPD patients, the day-to-day fluctuation in respiration is suitable for metereddose inhalers (MDI), DPI, or nebulizers [13]. In extreme settings of lung diseases, such as
stage IV COPD with forced expiratory volume (FEV1) < 50%, severe asthma (FEV1 <
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50%), or end-stage IPF with diffusion capacity of the lung for carbon monoxide (CO)
(DLCO) < 50%, respiration may be severely obstructed or restricted to the extent that
inhalation is ineffective because therapeutic deposition of particles cannot be achieved
[71]. This would be most apparent during acute disease exacerbations.
Tissue composition must also be considered. In the case of obstructive lung diseases,
such as asthma or chronic bronchitis, airway tissue composition changes significantly with
increases in mucus production, hypertrophy of the basement epithelial membrane and
surrounding smooth muscle, activated immune cells, and the many inflammatory factors
that they produce [72]. This also leads to changes in the composition of the aqueous and
mucous layers that line the airway thereby in most instances decreasing fluidity and
increasing viscosity [72]. Whether siRNA particles can traverse through this complex
admixture en route to target cells that lie underneath remains a major challenge in this
field.
In CF, the levels of endogenous DNA and actin filaments released from necrotic
neutrophils are elevated which further contributes to the dense mesh structure of the
airway [73]. The elevation of oxidative stress in CF increases disulfide cross-links between
mucin fibers which unfavorable changes mucus transport properties for particles [74]. The
size of the CF mucus mesh ranges from 60 to 300 nm [75]. Gene delivery vectors that
have been used in CF clinical trials have been shown to be incapable of efficiently
penetrating CF mucus, most likely due to the positivity charged surface of the formulations
that interact with negatively charged mucus.
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hyperinflation, elevated bacterial colonization in the lower airways, and increased
susceptibility to viral airway infections [76]. Significant efforts have been made to develop
siRNA therapeutics targeting mRNAs involved in the pathogenesis of COPD, including
RIP2, RPS3, MAP3K19, and CHST3 [7, 77]. Clinical trials using either viral or non-viral
delivery vectors have failed to show clinical benefits because of inefficient transfection of
target cells [39]. Poor ability of the particles to penetrate the mucus layer and aggregation
caused by PS are likely other reasons for the lack of success in clinical testing. COPD and
CF show activation of the alveolar macrophages, which provides additional challenge in
siRNA delivery [78]. In asthma, the barrier function of the airway epithelium is impaired
through defective tight junction formation. The tight junction proliferation results in
increased epithelial resistance. However, the pro-inflammatory cytokines and bacterial
toxins reduce the permeability of tight junctions, which means that the barrier properties
of the airway epithelium may vary with disease state [79].
Respiratory infections can be caused by a wide range of microorganisms in airways,
including bacteria and viruses. Respiratory infections are among the most common
reasons for hospitalization, partly because many infectious diseases have become difficult
to treat due to the rise of antimicrobial resistance. The respiratory syncytial virous (RSV)
replicates in the superficial layer of the respiratory epithelium, local delivery of siRNA to
the lungs is a rational approach to treat RSV infection [80]. There has been a clinical test
of an siRNA formulation, ALN-RSV01, which was directed against mRNA that exhibits
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specific anti-RSV activity [80]. Tuberculosis (TB) is a bacterial lung infection caused by
Mycobacterium Tuberculosis. RNAi approaches against TB typically aim to modulate the
host gene expression or host immune response instead of targeting the microorganism
directly due to the lack of the requisite machinery for RNAi [81, 82]. The 2020 pandemic
of the newly discovered coronavirus (SARS-CoV-2, COVID-19) spurred interest in siRNA
as a possible treatment [83]. In principle, multiple proteins encoded in the viral genome
can be targeted by siRNA. Zheng et al. designed 48 siRNA sequences that potentially
target the entire SARS-CoV genome, including ORFs needed for the translation of key
proteins [84]. Li et al. developed an siRNA which improved several symptoms of SARACoV, like fever, viral load, and acute alveolar damage [85]. He et al. demonstrated
synergistic antiviral effects through the use of siRNA pool targeting various structural
genes of the virus [86]. Since coronaviruses are positive ssRNA viruses that use ORF1a
and ORF1b replicases [87], siRNA could be an efficient approach to control the virus by
silencing the viral mRNA at particle stages. Future studies are called for to evaluate their
potential efficiency and safety.
Finally, a significant limitation for the greater success of inhalation therapies is in the
development of validated animal models of different lung disease states [2, 88].
Approaches to enhance RNA stability, tissue targeting, cell penetration and intracellular
endosomal escape are critical to realize the full potentials of RNAi drugs. This is important
in preclinical development to demonstrate efficacy, toxicity profiles, and ultimately the
establishment of appropriate human dosing regimens and how in vitro models can enrich
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pulmonary drug delivery research allowing for faster and more reliable clinical translation
[88, 89].
1.3.

Recent developments in the pulmonary siRNA delivery systems
Pulmonary siRNA delivery requires the use of suitable vectors that can safely

circumnavigate the unique environment and barriers in the lungs [2, 21, 22, 90]. In addition
to the delivery barriers discussed above, the stability of delivery systems is critical for
efficient pulmonary siRNA delivery. For the systemic siRNA delivery, the siRNA is rapidly
degraded with poor stability. Even though the nuclease levels are low in the lungs, the
particles stability in the presence of mucus and PS poses an obstacle. It is critical to
evaluate the impact of mucus and PS on the delivery systems. Study showed that the
cationic lipid-based siRNA nanocarriers (LipofectamineTM and RNAiMAX) were
incompatible with PS, however, the gene silencing potential of siRNA-loaded dextran
nanogels (DEX-NGs) was maintained in the presence of PS and the intracellular siRNA
delivery by DEX-NGs was enhanced [91]. Moreover, BALF contains inhibitory components
for non-viral gene transfer, and a study showed that mucin absorbed more to lipoplexes
than to polyplexes. However, the specific inhibitory components have not been identified.
The inhibition was most likely due to the charge in the surface charge of the gene vectors
[92]. The shielding of siRNA particles to circumvent interaction with the airway surface
layer (ASL) environment should be a focus for pulmonary administration.
In the following sections, we will review safety considerations and focus on the main
types of vectors employed in the pulmonary siRNA delivery. Because each type of delivery
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vector offers a unique set of advantages and disadvantages, there is a great need for
direct head-to-head comparisons of the different delivery systems to provide evidence for
their relative delivery performance. A good example of such a study is the evaluation by
Garbuzenko et al. of micelles, liposomes, mesoporous silica nanoparticles, cationic
dendrimers, quantum dots, and PEG in their ability to accumulate in the lungs [93].
1.3.1. Safety of pulmonary delivery systems
Careful safety evaluation of siRNA delivery systems is critical for their use because
of the finely tuned and sensitive immune response of the respiratory system to foreign
particles. Evidence shows that the observed toxic effects related to particulate delivery
systems are primarily mediated by inflammatory responses that often occur after particleinduced oxidative stress. The extent of the response is sensitive to the physicochemical
properties of the particles, including their size, chemical composition, surface properties,
charge, and shape [94]. The intracellular oxidative stress can regulate the expression of
endothelial cell adhesion molecules (CAMs) by transcription-dependent mechanism that
involves redox-sensitive transcription factors and result in the activation of the MAPK and
NF-κB pathways, which leads to the release of the inflammation-related cytokine [95].
Multiple studies show that most positively charged particles induce lung inflammation
following pulmonary delivery. For example, positively charged chitosan microparticles and
gold and Fe3O4 nanoparticles caused inflammatory lesions in rodents [96]. Rats given
positively charged graphene nanoplates exhibited greater pulmonary inflammation than
negatively charged counterparts [97]. Mice administered with cationic liposomes and
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cationic NLCs developed pulmonary inflammation, while neutral and anionic liposomes
and anionic NLCs exhibited normal lung histology [97, 98]. For some particles, however,
negative surface charge can elicit stronger release of proinflammatory cytokines than
positively charged particles [99]. For example, in RAW264.7 macrophages, negatively
charged silica nanoparticles induced the highest secretion of proinflammatory TNF-α
compared to neutral and positively charged silica NPs [100]. Negative surface charge on
quantum dots enhanced the mRNA levels of TNF-α in A549 cells, whereas IL-1β
expression was enhanced by all quantum dots regardless of their surface charge [101].
Lipid-based delivery vectors can induce toxicity and non-specific activation of
inflammatory cytokines and interferon response [102], while alveolar macrophages are not
activated by exposure to polymeric microspheres [103].
To reduce non-specific toxicity to normal lungs following pulmonary delivery,
nanoparticles with site-specific targeting and triggered release characteristics have been
evaluated. PS-based pH-sensitive nanoparticles were cytotoxic to lung tumor cells but
proved safe to healthy lung cells, indicating a possible selective toxicity can be achieved
[104]. A biodegradable PLGA nanoparticles did not induce apoptosis, oxidative stress or
cell cycle arrest compared with nonbiodegradable forms [105]. A block copolymer
composed of PEG and PAsp(DET) achieved safe gene transfection without inducing
severe lung inflammation [106]. Covalent siRNA conjugates are among the most
promising delivery approaches with a usually favorable toxicity profile [107]. Further,
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exosomes as a new class of delivery systems did not trigger the lung immune response
and were less likely to aggregate [45].
1.3.2. Lipid-based carriers for pulmonary siRNA delivery
A majority of commercial siRNA transfection agents are based on cationic lipids and
some of them have been used in pulmonary delivery [108]. Lipid-based formulations used
in pulmonary siRNA delivery include liposomes, lipoplexes, and nanostructured lipid
carriers (NLC) [109]. Despite their outstanding transfection efficacy, the presence of
cationic lipids in many of the formulations raises toxicity concerns associated with nonspecific activation of inflammatory cytokines and interferon responses [110]. The
inflammation response can be minimized by incorporating PEG lipids into the formulations
[111]. However, a balance must be found between the positive surface charge and PEG
surface density. The exclusive use of neutral lipids such as cholesterol in the form of
covalent siRNA-lipid conjugates may reduce the toxicity and inflammation associated with
cationic lipids [112].
Incorporation of specific ligands to achieve receptor-targeted siRNA delivery has
been explored in various delivery strategies, including pulmonary delivery. Tumor-specific
receptor luteinizing hormone-releasing hormone (LHRH) has been used in NLC
formulations of siRNA and paclitaxel (PTX) in pulmonary treatment of lung cancer [113].
Inhalation delivery of the targeted formulation showed limited adverse effects and clearly
outperformed non-targeted formulation as well as intravenously administered control.
Oligolysine epithelial-targeting peptide have been used as part of DOTMA/DOPE
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formulations to deliver siRNA to mediate silencing of airway epithelial ENaC [114]. siRNA
encapsulated in a vitamin A-coupled liposome efficiently suppressed HSP47 expression
and induced apoptosis of myofibroblasts in the IPF model [115]. When Genzyme GL-67
cationic formulation composed of DOPE and DMPE-PEG, was clinically tested for the
delivery of DNA for cystic fibrosis treatment [116], chloride abnormalities were improved
and bacterial adherence in patients’ lungs was reduced.
Lipids have also been widely used as components of other of siRNA delivery systems.
For example, hybrid lipid-polymer nanoparticles containing PLGA and dipalmitoyl
phosphatidylcholine (DPPC) have shown great potential for pulmonary siRNA delivery
[117]. Similar hybrid nanoparticles have been optimized for scale-up, spray-drying
production to fabricate physiochemically stable, biologically functional powders with
properties optimal for pulmonary siRNA delivery [118].
1.3.3. PS for pulmonary siRNA delivery
Recent studies have shown that PS can be used to prepare nanoparticles with control
over their biological fate, toxicity, pulmonary distribution, cell targeting, and intracellular
delivery [44]. In the context of pulmonary siRNA delivery, PS can be used as carriers in
the design of unique and bio-inspired systems to improve the siRNA distribution at the
alveolar interface in the deep lung. The PS-based delivery strategy was first reported in
1994 in a study that used poly(lysine) conjugated to SP-B to deliver DNA into airway cells
in vitro [119]. Because SP-B is positively charged, it is one of the most investigated PS for
pulmonary delivery [33, 34, 120, 121].
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Amphiphilic cationic KL4 peptide was developed and tested as a synthetic SP-B
mimic [122]. KL4 is one of the active compounds in Surfaxin, an FDA-approved
intratracheal PS suspension for the prevention of RDS [122]. The KL4 peptide formed
complexes with siRNA and helped in delivery in lung epithelial cells. Compared with
conventional lipoplexes, the KL4/siRNA complexes remained stable and mediated
efficient siRNA transfection in the presence of PS [123].
Systematic studies have been conducted to delineate how lipid composition affects
pulmonary siRNA delivery with SP [29, 30, 33, 34, 44, 91]. Hybrid nanoparticles consisting
of siRNA-loaded dextran hydrogel core were coated with Curosurf® (a clinically used
porcine PS) as an outer shell. The studies demonstrated that the outer layer of PS
enhanced the intracellular siRNA delivery [34, 44]. SP-B was identified as the key
component responsible for the enhanced siRNA delivery following pulmonary
administration [30]. SP-B can also promote siRNA delivery to other cell types, suggesting
a more universal carrier potential [29].
1.3.4. Polycation-based systems for pulmonary siRNA delivery
The utility of polycations as siRNA delivery systems called polyplexes has been
explored for several decades. A plethora of synthetic and natural polycations have been
pursued for pulmonary delivery of siRNA, including PEI and chitosan [60].
PEI has become one of the most widely studied siRNA delivery vectors because of
its highly modifiable amine-rich structure that facilitates effective cellular internalization
and endosomal escape [124-127]. Clinical application of PEI or its conjugates has been
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so far limited by toxicity concerns [125]. Modification of PEI with neutral or anionic moieties,
like PEG, perfluoroalkyls, hyaluronic acid, and attachment of targeting moieties has been
shown to reduce toxicity [125-128]. Transferrin-PEI was designed to selectively deliver
siRNA to activate T cells in the lung to avoid potential systemic effects [125]. An
investigation by Merkel et al. showed that polyplexes formulated with PEG-PEI
demonstrate better targeted delivery of siEGFP compared with PEI polyplexes via
intratracheal administration [126]. In our previous study, we designed polyplexes based
on CXCR4 (C-X-C chemokine receptor type 4) inhibiting PEI derivative (PEI-C) for
pulmonary delivery of siRNA as a combination treatment of IPF [129]. Similarly, pulmonary
co-delivery of chemotherapy and siRNA can improve therapeutic efficacy in lung cancer
[130]. Doxorubicin was conjugated to PEI using a pH-sensitive cis-aconityl linker and the
polymer-drug conjugate was then used to condense siBcl-2 into polyplexes [130]. The
combined polyplexes exhibited enhanced antitumor efficacy compared with either
monotherapy.
Chitosan is another polycation that has been evaluated for pulmonary siRNA delivery
[131]. Findings showed that chitosan dry powder prepared by spray freeze drying
delivered siRNA against VEGF decreased the number of metastatic lesions in the lungs
[132]. A limitation of chitosan is its poor solubility at physiological pH [131, 133]. Various
chemical modifications of chitosan have been used, including PEG conjugation.
Piperazine substitution of chitosan increased aqueous solubility at physiological pH,
lowered cytotoxicity, and increased gene silencing efficacy. The system was used for
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inhalation delivery with good tolerability [131]. Xu et al. developed inhalable chitosan
particles for co-delivery of doxorubicin and siRNA. The nanoparticles, which were
embedded in poly-L-lactide (PLA) were highly stable and achieved deep lung deposition
with excellent aerodynamic performance and sustained release of doxorubicin [134].
Cationic dendrimers have well-defined hyperbranched 3D structure with spherical
shape [135]. The high density of surface groups allows for specific ligand modification for
improved siRNA delivery [136]. Generation 4 PAMAM dendrimer was used for siRNA
delivery using pressurized metered-dose inhaler (pMDI) [137]. The dendrimer/siRNA
polyplexes were stabilized with mannitol and given with hydrofluoroalkane propellant to
achieve siRNA delivery to alveolar epithelial cells. Triphenyl phosphonium modification of
PAMAM dendrimers achieved successful aerosol delivery to the lungs using portable
inhalers [138]. Dendrimer/siRNA polyplexes prepared using microfluidic assembly were
successfully evaluated in spray-dried microparticle form [139].
Virus-inspired polymer for endosomal release (VIPER) was developed based on a
polycation block to electrostatically condense siRNA into polyplexes [140]. Pulmonary
administration of VIPER polyplexes in mice improved accumulation of the particles in both
the bronchial and alveolar epithelium.
Compared with simple polyplexes, core-shell polymeric NPs can encapsulate siRNA
in a polymer matrix to improve siRNA stability in the formulation [141]. Receptor-targeted
nanoparticles comprising multifunctional mixtures of cationic segments (oligolysine
epithelial-targeting peptide and the liposome DOTMA/DOPE) demonstrated effective
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mucus penetration and siRNA delivery to airway epithelium with low cytotoxicity, high
transfection efficiency, and increased gene expression [114].
Fluorinated polycations emerged as attractive materials for nucleic acid delivery due
to their unique serum resistance associated with the lipophobic and hydrophobic features
of fluorocarbons [142]. Fluorination as an effective strategy for transmucosal nucleic acid
delivery using guanidinated and fluorinated bifunctional helical polypeptides was reported
recently [51]. The authors found that fluorination prevented undesired dissociation and
decreased the mucin aggregation, which improved mucus penetration. This was due to
reduced interactions between the polyplexes and the mucins. We have recently taken
advantage of the fluorinated polycations in a pulmonary delivery strategy to successfully
modulate the immune response and enhance anti-PD-L1 immunotherapy in lung cancer
[143].
1.3.5. Peptide-based systems for pulmonary siRNA delivery
Bioactive cationic peptides represent an interesting class of siRNA delivery systems
due to the possibility to take advantage of their inherent biological activity to improve the
efficacy of the delivery process. Cell penetrating peptides (CPPs) used alone or covalently
conjugated to polymers are a common example. CPPs consist of short amino acid chains
and can interact with the plasma membrane to allow for cellular uptake during siRNA
delivery [144]. A recent study shows that the silencing of chitinase-3-like-1 (Chi3l1)
expression in the lung using CPPs-siRNA complexes (dNP2-siChi3l1) inhibits lung
metastasis with enhanced Th1 and cytotoxic T-lymphocyte responses [145]. However,
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when compared to naked siRNA, conjugation of siRNA to transactivator of transcription
and penetrating CPPs failed to increase siRNA-mediated gene knockdown in healthy
mouse lung [146].
1.3.6. Emulsion-based systems for pulmonary siRNA delivery
Direct formulation delivery to a disease site provides an attractive approach to treating
lung disease. In our previous work, we reported that combining CXCR4 inhibition with
plasminogen activator inhibitor-1 (PAI-1) silencing could serve as a promising strategy for
treating IPF [129]. However, simple cationic polyplexes poorly penetrated the lung mucus
layer [49]. Perfluorocarbons (PFCs) are biocompatible materials widely used as
ultrasound contrast agents, in treating lung diseases, and in organ transplantation
because of their high oxygen-dissolving capacity [147-149]. We have reported that PFC
emulsions could improve cellular siRNA delivery to attenuate lung cancer metastasis, IPF,
and ALI [147, 148]. The PFC emulsion polyplexes formulated for pulmonary siRNA
delivery improved cellular internalization and endosomal escape when compared with
polyplexes. Furthermore, PFC in PLGA-PEG emulsions can serve as an agent for highly
efficient organ reoxygenation [150]. A reverse water-in-PFC emulsion has been evaluated
as a potential drug delivery system for pulmonary administration using pMDIs [151-153],
but has not yet been used for siRNA delivery.
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1.3.7. Inorganic nanoparticles for pulmonary siRNA delivery
In recent decades, various inorganic materials have been developed for therapeutic
and diagnostic applications [154]. Among them, mesoporous silica nanoparticles (MSN)
and hybrid lipid-calcium phosphate nanoparticles have shown promise in pulmonary
siRNA delivery. MSN are well-suited for co-delivery of small molecule drugs and siRNA
due to large porous surface area. LHRH-targeted MSN were tested in delivery of
anticancer drugs and siRNA to treat lung cancer [155]. When compared with intravenous
injection, where only 5% of the injected dose accumulated in the lung, pulmonary delivery
of the MSN increased lung accumulation to 73% and prevented the absorption into the
systemic circulation. Hybrid lipid-calcium phosphate nanoparticles were developed for
pulmonary delivery of siRNA to abate lung inflammation [156]. The nanoparticles
consisted of a calcium phosphate core coated with siRNA directed against proinflammatory mediators, encapsulated in PLGA, and finally coated with the outer layer of
PEI. Nasal instillation of the particles led to a significant reduction of target gene
expression and modulation of the inflammation response [156]. Conde et al. developed
functionalized gold nanoparticles for targeted delivery of siRNA to cancer cells toward
effective silencing of the specific target oncogene [157].
1.3.8. Naked siRNA for pulmonary delivery
The term “naked siRNA” refers to the delivery of siRNAs without any delivery vectors.
Several studies suggested that naked siRNA delivery is compromised because of the
instability and poor pharmacokinetic performance in systemic circulation. However, for
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local pulmonary delivery, naked siRNA has shown promising results in the treatment of
lung infections [82, 132, 158-161]. To improve siRNA stability and efficacy without using
delivery systems, the siRNA was either chemically modified or conjugated to other
biomolecules. Zhang et al. demonstrated that pulmonary delivery of siRNA can be
achieved by intranasal administration without any vectors [162], although many of the
mechanistic considerations, such as mechanism of cell uptake, are not clear.
Nevertheless, the delivery of naked siRNA has been extended to clinical trials. A modified
form of siRNA (ALN-RSV01) was administered using nasal spray and the treatment
reduced RSV infection. In addition to liquid formulations, dry powder forms of naked siRNA
also showed gene silencing effects [163, 164]. Kohie et al. showed that naked siRNA was
not affected by nebulization when processing using ultrasonic, air-jet, and vibrating-mesh
nebulizers [165].
1.3.9. Microparticles for pulmonary siRNA delivery
Aerosol particles with aerodynamic diameter 1-5 μm are optimal for penetration into
the deep lungs and lower airways. Despite their large size (5-30 μm), large porous hollow
particles (LPHPs) can achieve the desired aerodynamic size range via enhanced porosity
within the particles, which aerodynamically balances the large size [166]. A main
advantage of this approach is that the actual geometric size is too large for phagocytosis
by alveolar macrophage, which permits therapeutics retention for longer periods of time.
LPHPs show other beneficial features, including high dispersibility from an inhaler and
enhanced deposition in the lungs upon inhalation. The large particle size reduces
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fractional surface area of particle-particle contact in a dry powder or liquid suspension and
leads to decreased tendency to aggregate. A dry powder inhalable PLGA LPHP containing
insulin showed prolonged drug release and decreased macrophage uptake and
mucociliary clearance in vivo compared with nonporous particles [167]. LPHP of PEGPLGA containing heparin exhibited reduced the uptake by isolated rat alveolar
macrophages in vitro than small nonporous particles [168, 169]. A 3D-printed micromixer
was used for preparation of siRNA-dendrimer nanocomplexes, which were then
processed into nano-embedded macroparticles and shown to retain siRNA integrity and
bioactivity [139]. siRNA can be encapsulated in PLGA microparticles optimized using a
double emulsion technique, and the results showed significant downregulation of the
target gene expression compared to negligible knockdown using commercial transfection
reagents [42, 170]. Xu et al. developed PLA porous microparticles which contained siRNAloaded chitosan and doxorubicin by the supercritical anti-solvent process. The particles
exhibited a favorable aerodynamic performance and sustained drug release that led to
higher anticancer efficiency [134]. A porous silicon micro/nano composite was reported to
deliver siRNA to the lungs with melanoma metastasis [171].
1.3.10. Exosomes for pulmonary siRNA delivery
Exosomes are a type of extracellular nanovesicles released from living cells.
Exosomes were once thought to be a mechanism for removing unwanted proteins, but we
now know that they are also involved in intercellular communication. The fact that
exosomes can bind a wide range of surface receptors makes them interesting option for
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therapeutic siRNA delivery. Recent studies suggest that exosomes regulate the
development of lung inflammation in response to diverse stimuli, potentially providing
novel therapeutic and diagnostic targets for ALI/ARDS [172, 173]. An inhaled exosomes
have been developed for efficient delivery to inhibit or activate the alveolar macrophages
and also generate pulmonary immune response [45]. Importantly, these serum-derived
exosomes themselves did not trigger the lung immune response. Intratracheal siRNA
delivery using host serum-derived exosomes attenuated LPS-induced inflammation in
alveolar macrophages [45]. Intratracheal instillation deposited exosomes in alveolar
regions rather than in bronchioles and macrophages were the main recipient cells. The
presence of surface proteins in exosomes may facilitate uptake by specific cell types in
the lungs and avoid uptake by macrophages. Exosomes from human induced pluripotent
stem cells were used as siRNA delivery vectors to silence ICAM-1 expression as a
potential treatment of ALI. Recent study showed the potential of exosomes in delivering
siRNA in an important in vitro airway model [174].
1.4.

Pulmonary siRNA inhalation delivery: Promise of dry powder inhalers
Therapeutic delivery via inhalation provides direct access to the target cells of siRNA

therapy in a relatively non-invasive manner. Early developmental and preclinical studies
of pulmonary siRNA delivery typically use intratracheal and intranasal administration for
their simplicity. However, these administration routes are not usually directly translatable
to clinical use due to considerable risks and discomfort for patients. Hence, the
development of inhalation aerosol systems is critical for the practical translation of
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experimental siRNA delivery systems from the laboratory to clinical use [175]. The three
most common used commercial aerosol inhalation systems are nebulizers, pressurized
metered-dose inhalers (pMDIs), and dry powder inhalers (DPIs). Nebulizers generate
inhalable micro-sized liquid droplets that can carry large amounts of siRNA delivery
vectors per droplet and reach virtually all areas of the lungs. Some of them have already
been successfully used in clinical pulmonary nucleic acid delivery. A nebulized cationic
lipid/DNA formulation has been tested in phase I clinical trial in CF [116]. More recently,
two additional inhalable RNAi-based products have entered clinical trials: ALS-RSV01 [80,
176] and ExcellairTM [177]. ALS-RSV01 uses cholesterol-siRNA conjugate to treat RSV
infection in lung transplant patients [176]. ExcellairTM (whose phase II trial was
discontinued in 2015) was aimed at treating asthma through silencing Syk [177].
Dry powder siRNA formulations have several advantages over liquid aerosol
formulations, including better stability, ease of handling, and lower cost of storage and
transportation [178]. Nevertheless, the development of DPIs for pulmonary siRNA delivery
remains limited due to unresolved issues related to destabilization of the siRNA and the
carrier system caused by the stress of heating, freezing, or spraying [179]. Spray drying,
spray freeze drying (SFD), and supercritical fluid drying are the three major dry powder
techniques applicable for the use in siRNA formulations [179]. Even the naked form of
siRNA could be formulated into an inhalable dry powder using co-spray-drying with
mannitol and l-leucine (a dispersion enhancer), while maintaining the integrity of siRNA
[163]. An early example of siRNA formulation in the form of inhalable dry powder using
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spray drying technology dates back to 2010 [180]. The initial formulation was improved by
incorporating DOTAP into the original PLGA matrix to improve encapsulation and
transfection activity of the siRNA in the spray-dried formulations [181]. Inhalable dry
powder formulations of pH-responsive peptide/siRNA complexes were successfully
produced by spray drying without compromising the physical integrity and biological
activity of siRNA [182]. SFD is a multi-step process including a spray-freezing step and a
freeze-drying step. The powder production by the SFD maintained the physicochemical
properties of polyplexes without negating transfection efficiency [183]. SFD can provide
high recovery of the powders even when the formulation amount is small, which makes
SFD well-suited for the task due to the relative expense of siRNA [184]. SFD process
parameters and choice of excipients could be optimized to maintain integrity and biological
activity of siRNA, for example by co-spraying with carbohydrates and using low inlet
temperatures [181]. Similarly, co-spray drying with mannitol and L-leucine as excipients
also successfully preserved siRNA integrity even in the absence of any delivery system
[163]. The presence of siRNA also alters the molecular arrangement and solid-state
composition of carbohydrate excipients during the spray drying process [185].
Among the polycation-based siRNA delivery systems, PEI and chitosan have been
the most often used vectors for the preparation of dry powders. SFD was used to prepare
chitosan formulation with siVEGF, which was successfully used for pulmonary delivery to
treat metastatic lung cancer [132]. PEI/siRNA powder with a spherical and highly porous
structure was also prepared by SFD with high aerosol and lung delivery performance [186].
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Merkel et al. demonstrated successful spray drying of PEI polyplexes in the form of nanoembedded microparticle powder [124]. The authors optimized the spray-drying
parameters to generate powder with appropriate aerodynamic properties suitable for deep
lung deposition.
In several published studies, the inhalable siRNA dry powder formulations were
limited by the siRNA content, which was too low to be moved to clinical study. Inhalable
spray-dried powder formulation with high siRNA loading (>6% w/w) was developed using
human serum albumin as a dispersion enhancer to improve aerosol performance [187].
As a dispersion enhancer, albumin favorably modifies the surface properties of the spraydried powder leading to the fine particle fraction consistently over 50% [187]. L-leucine is
often used as the dispersion enhancer, but due to its small size compared to
macromolecular siRNA, the benefits of L-leucine in siRNA formulation were modest [163].
1.5.

Conclusion
In this review, siRNA delivery barriers and recent approaches were described.

Pulmonary delivery of siRNA has gained increased attention due to the specific physiology
of the lung and characteristic properties of siRNA. However, how to translate laboratory
studies to clinical practice and the difficulties that exist in evaluating this route of
administration still remain a significant challenge. Even though the DPIs seem the best
choice for pulmonary siRNA delivery, more studies are required in regard to dose, siRNA
loading, optimal excipients, and inhaler device for maintenance of siRNA stability and
biological function.
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2. CXCR4 as a therapeutic target in fibrosis and pancreatic cancer
CXCR4 is a G-protein-coupled receptor which involved in several physiological
processes in immune system and hematopoietic. CXCL12 is the chemokine ligand of
CXCR4. CXCL12/CXCR4 axis plays important role in several disease, including cancer,
fibrosis, and some injured (acute and chronic) disease [188].
2.1.

CXCL12/CXCR4 axis
Chemokines are a class of small, secreted cytokines with 8-12 kD molecular weight

and functions. They are known for the mediation of immune cell recruitment and regulate
many of tissue and cell functions. Chemokine can be categorized into 4 subfamilies (C,
CC, CXC and CX3C) based on the arrangement of the first two cysteine residue’s location
beside the amino terminus [189]. CXCL12, also referred to as stromal cell-derived factor1 (SDF-1), binds to CXCR4 then induces downstream signaling pathways, including cell
proliferation, migration, and cancer cells metastasis [190]. CXCL12 can be secreted by
stromal cells [191], fibroblasts, and epithelial cells, which regulating hematopoietic cells
trafficking and secondary lymphoid tissue architecture [192]. CXCR4 induces downstream
signaling pathway via G proteins and GRKs, which subsequently induces many signaling
pathways (MAPK, AKT, PI3K, ERK1/2) after binding with CXCL12, and then promoting
several cellular functions, such as actin polymerization, cells skeleton rearrangement,
cells survival, proliferation, and migration [190].
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2.2.

CXCR4 in fibrosis
CXCR4 not only overexpressed in the cancer tissue, but also in some fibrosis disease,

such as, peritoneal fibrosis [193], IPF [194], liver fibrosis [195], cardiac fibrosis [196], and
skin fibrosis [197], et al. In lung tissue, multiple type of cells express CXCR4, especially in
fibrotic lungs, including fibroblasts and myofibroblasts, epithelial cells, vascular endothelial
cells and some inflammatory cells (alveolar macrophages) [198]. Jade Jaffar evaluated
the CXCR4+ cells in lung tissue of patients with IPF, and they found that CXCR4 is
overexpressed in IPF patients than the non-disease control (NDC) [194]. Moreover, some
of the study suggested that CXCL12/CXCR4 axis resides in lung fibroblasts contributed
to fibrotic by directing activating lung fibroblasts [199]. Epithelial-to-mesenchymal
transition (EMT) of human peritoneal mesothelial cells (HPMCs) is considered as the main
mechanism involved the origination and development of the peritoneal fibrosis [200].
During the fibrosis stages, TGF-β activation results in secretion and expression of CXCL12
and its receptor CXCR4, which resulting in potential of HPMCs migration and ECM
deposition in the fibrosis foci [193]. In the liver fibrosis, more of the activated hepatic
stellate cells (HSCs) lead to the ECM deposition. Study proved the HSCs express CXCR4
receptor both in vivo and in vitro [201].
Some of the paper developed nanomedicine related to CXCR4 whereas CXCR4
served as the therapeutic target for treating the fibrosis disease. The following are some
examples. Combined delivery of sorafenib and MEK inhibitor using CXCR4-targeting NPs
can prevent ERK activation in activated HSCs and has anti-fibrotic effects in the CCl4-
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induced murine models [202]. The inhibition of the CXCL12/CXCR4 biological axis can
attenuated the severe of fibrosis progression. Treatment of the mice lung fibrosis models
with CXCR4 antagonists, including TN14003 [203], MSX-122 [204] and ADM3100 [205],
attenuated the progression of lung fibrosis significantly. Dual-functional NPs targeting
CXCR4 and delivering antiangiogenic siRNA reduce liver fibrosis [195]. Khan A designed
a liposome based on the CXCR4-receptor-targeter shown promising the therapeutic effect
for treating peritoneal fibrosis [193]. CXCR4 antagonism reduce cardiac fibrosis and
improves cardiac performance in dilated cardiomyopathy [196].
2.3.

CXCR4 in cancer therapy
CXCR4 was firstly found to target CD4-positive T-cells and function as a co-receptor

for entry into T-tropic (X4) HIV virous. Then, CXCR4 has been confirmed expressed in
many types of cancers. CXCR4 together with its ligand CXCL12, CXCL12/CXCR4 axis,
controls and triggers downstream signaling pathway and variously involved in tumor cells
proliferation, migration, and survival. Several studies suggested that the overexpression
of CXCR4 has significantly role in cancer stem cells [206]. CXCR4 in promoting
inflammatory colorectal cancer progression via recruiting immunocytes and enhancing
cytoskeletal remodeling by lncRNA XIST/miR-133a-3p/RhoA signaling [207]. Another
study suggested that cancer-associated fibroblasts (CAFs) derived from endometrial
cancer (EC) tissue promoted EC progression via the CXCL12/CXCR4 axis in a paracrineor autocrine-dependent manner [208]. The secreted CXCL12 drives the CXCR4+ cells
migration and lead to the organ-specific metastasis, such as lungs, liver, and lymph nodes
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show higher of CXCL12 expression which indicate the most common organs for the
CXCR4+ receptor of cancer metastasis [209].
Blocking CXCR4 can alleviate cancer progression and metastasis. Various studies
have been evaluated to inhibit CXCL12/CXCR4 axis for cancer treatment. In the past
decades, several small molecules, CXCR4-binding peptides, siRNA, and polymer based
on CXCR4 inhibition moiety have been evaluated to inhibit CXCR4-mediated processes
in cancer treatment. Plerixafor (AMD3100), one of the small molecules CXCR4 specific
antagonists, has been approved by US FDA for autologous transplantation in patients with
Non-Hodgkin’s Lymphoma and multiple myeloma in 2008 [210]. Blocking of CXCR4 with
inhibitors exhibit high efficacy for cancer treatment via inhibiting metastasis, improving the
tumor sensitivity to the chemotherapy, radiotherapy, and immunotherapy [211]. For
examples, one of study proved that blocking CXCR4 attenuates desmoplasia and
increases T-lymphocyte infiltration which improve immunotherapy in metastasis breast
cancer [212]. Sison E.A et al developed Protein Epitope Mimetic POL5551, a novel and
potent antagonist of CXCR4, has activity at nanomolar concentrations in decreasing
CXCR4 antibody binding, blocking CXCL12 mediated ERK1/2 phosphorylation, inhibiting
CXCL12-induced

chemotaxis,

and

reversing

stromal-mediated

protection

from

chemotherapy [213]. Various of nanomedicine have been developed based on the CXCR4
inhibition for the effective cancer treatment. For example, CXCR4-targeted PEGylated
PLGA NPs conjugated with CXCR4 inhibitor peptide (LFC131) codelivery of sorafenib
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offer an effective strategy for enhancing the therapeutic efficacy on Hepatocellular
carcinoma (HCC) [214].
3. Pancreatic cancer
Pancreatic ductal adenocarcinoma [PDAC, also referred to as pancreatic cancer (PC)]
is the fourth leading cause of cancer-related deaths [215]. Unfortunately, PC is usually not
diagnosed until late stage with the metastasis spread which led to the poor prognosis of
PC. Clinically, even though the developments in detection and management of PC, only
~4% of patients will live 5 years after diagnosis [216]. Moreover, surgical tumors only
improve 15~20% of patient’s survival, and PC patients response poorly to most of
chemotherapeutics [216]. Overall, it is unmet medical need to develop the better
therapeutics.
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3.1.

Clinical challenges of therapeutic of PC

Figure 1.2 The unique clinical challenges of PC therapeutics [Adapted from [217].

The specific pathological challenges of PC therapeutics show rise to the development
of PC treatment (Figure 1.2 [217]). For example, the pancreatic stellate cells (PSC)
generate fibrotic foci surrounding with the tumor cells to promote the tumor cells survival
and metastasis [218]. Moreover, the fibrotic area inhibits therapeutics delivery and
penetration. Indeed, dense fibrotic stroma forms more than 80% of the PC tumor mass,
which serve as one of the histopathological features of PC [217]. Moreover, the fibrotic
dense stroma content in PC patients is related to the patient survival outcome [219].
Besides, this desmoplastic contributes to the hypoxia condition in PC solid tumors then
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promotes the chemoresistance and heterogeneity of tumor cells, which play important
roles to slow the PC treatment [220]. Herein, PSCs are considered as key cellular
therapeutic targets to remodulate the fibrotic condition in PC. When designing the
strategies for PC treatment, it is important to evaluate both the tumor cells and the
surrounding PSCs.
3.2.

siRNA delivery for treating PC

Researchers have identified various of novel cancer-related genes that involved in the
PC tumor initiation, progression, and metastasis. Many important genetic alterations have
been investigated to be involved in the PC, which contain KRAS and tumor suppression
inactivators (TP53, SMAD4, CDKN2A) [221]. It shown highly promising to selectively
knockdown these genes to impede the tumor progression and extended patient survival.
RNA interference (RNAi) can be naturally occurred in mammalian cells, and this gene
silence mechanism can be used to selectively inhibit the therapeutic gene targets. RNAi
NPs not only can target the tumor cells that impeded the tumor progression but can
selectively target PSCs that decrease the fibrotic foci which to normalize tumor
vasculature and improve the tumor accumulation and penetration of therapeutics.
siRNA consists of double-stranded RNA with ~21-23 base pairs, which can selectively
knockdown the expression of targeted gene and provide potential power to treat many of
human disease including PC [222]. siRNA come up as potential and selectively targeted
therapeutic approach. Moreover, some of clinical trials based on siRNA have been under
evaluated now [223]. However, there are many challenges when researchers designing
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siRNA-based therapeutics for treating PC, which including the poor stability, poor cellular
uptake and endosome escape with low transfection ability, poor solid tumor penetration
and off-target effects, et al. Consequently, it is urgent for the development of effective and
safe therapeutics based on siRNA strategies for PC treatment. Here are some examples
that demonstrating the potential of siRNA-based therapeutics for effectively treating PC.
1) Lipid and polymer-based NPs: Lipid-based NPs (LNPs) which contain pH-sensitive
cationic lipid have been designed to effectively delivery siRNA for treating PC [224].
Cationic polymer shown great potential as siRNA delivery vehicles, such as PEI. 2)
Inorganic-based NPs: Gold NPs and carbon nanotubes have been evaluated as highly
effective siRNA delivery vehicles for cancer treatment [222]. 3) Hybrid-based NPs: One of
the hybrid NPs have been designed which comprised of two cationic polymers, DOTAP
and DOPE as well as cholesterol to self-assemble siRNA into a cationic nanocomplex for
treating cancer [225].
3.3.

Conclusion

Overall, the potential of siRNA strategies to selectively silence the tumor promoting
exhibit great potential for PC treatment. Several of pre-clinical studies based on siRNA
therapeutics shown promising anti-tumor and metastasis ability. However, there are
various challenges to transfer these promising preclinical finding to clinic. It is crucial to
establish the stronger collaborations between chemists, pathophysiologist, biologists,
formulation scientist, and clinicians if we want to revolutionize the PC treatment.
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Chapter 2: Perfluorocarbon Nanoemulsions Enhance Therapeutic siRNA Delivery
in the Treatment of Pulmonary Fibrosis

Please note that this part of the dissertation was published in the Advanced Science
(Ling Ding et al, 2022). As the first author, I designed the experiments, collected, and
analyzed the data, and wrote the paper. Prof. Oupicky guided me on this project. Siyuan
Tang, et al, helped me with the experiments. Prof. Oupicky, Prof. Knoell, Prof. Wyatt, et
al, helped with editing the manuscript. All the co-authors agree with including their work in
this dissertation.
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial lung
disease. The progression of IPF is categorized by decline of lung function, progressive
dyspnea, nonproductive cough, and decreased quality of life [237]. Increasing rates of
hospital admissions and deaths due to IPF underlie the need for better therapies [237].
Development of pulmonary fibrosis is also implicated in severe COVID-19 infections,
further underscoring the urgency [238, 239].
Current views of the pathogenesis of IPF rely on repeated subclinical epithelial injury
combined with augmented epithelial aging that leads to abnormal repair and the formation
of interstitial fibrosis by myofibroblasts [240]. The senescence of alveolar epithelial cells
and activation and differentiation of myofibroblasts is a central phenotype that promotes
IPF [241]. Fibroblastic foci, where disordered collections of type II alveolar epithelial cells
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are present with fibroblasts, are considered a key pathological feature of IPF [242]. After
decades of clinical trials, there are currently only two FDA approved anti-fibrotic
medications that are considered safe and somewhat effective, nintedanib and pirfenidone
[243]. The mechanism of pirfenidone is not fully understood, but it possesses both antiinflammatory and antifibrotic effects, whereas nintedanib, a tyrosine kinase inhibitor,
specifically blocks fibroblast proliferation, migration, differentiation, and the formation of
extracellular matrix (ECM) [244].
With the recent regulatory approvals of the first siRNA therapeutics [15,18], the
development of additional siRNA-based medicines for a broad range of diseases has
become increasingly feasible. Direct delivery of siRNA into the lungs has beneficial
characteristics, such as avoidance of undesired serum interactions and degradation.
However, the anatomy of the respiratory tract is complex and creates obstacles for
effective delivery. Several preclinical studies in pulmonary fibrosis demonstrated efficacy
using siRNA formulations aimed at silencing the expression of collagen-specific
chaperone heat shock protein 47 (HSP47) [115], Janus kinase type 2 (JAK 2) [245], E1A
binding protein P300 (EP300) [246], plasminogen activator inhibitor-1 (PAI-1) [129, 148],
and NLR family pyrin domain containing 3 (NLRP3) [247]. Related to this, two human
clinical trials have utilized siRNA inhalation strategies to treat respiratory syncytial virus
(RSV) (ALN-RSV01)[248] and asthma (ExcellairTM) via Syk silencing [249].
Perfluorocarbon (PFC) nanoemulsions are versatile soft nanomaterials with a unique
set of properties suitable for multiple biomedical applications, including drug delivery and
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bioimaging. Unlike self-assembled soft materials like micelles, PFC nanoemulsions are
kinetically stable systems where the PFC oil phase is stabilized with amphiphilic
surfactants [250, 251]. Nanoemulsions have a potentially large loading capacity for active
molecules, with release properties controlled by the nature of the oil phase and choice of
surfactant. PFC nanoemulsions also have high oxygen solubility, which prompted their
first development as blood substitutes. Perfluorooctylbromide (PFOB) is among the most
commonly used PFCs in biomedical applications [252, 253]. PFOB nanoemulsions have
been studied in the treatment of cancer and atherosclerosis [254]. Pulmonary
administration of PLGA-PEG/PFOB nanoemulsions have been shown to improve lung
ventilation [150]. Photodynamic therapy has been another successful application of PFOB
emulsions, which benefits from high oxygen solubility [252, 255].
Chronic dysfunctional inflammatory response and aberrant self-repair are critical
factors in progressive IPF. This involves the recruitment of immune and mesenchymal
cells by chemokines and chemokine receptors, which play a critical role in cell migration
and also serve as potential therapeutic targets [256]. Invasion of fibroblasts into the
alveolar region results in collagen deposition and fibroblast differentiation into
myofibroblasts [257]. The G-protein coupled C-X-C chemokine receptor type 4 (CXCR4)
is a candidate therapeutic target in IPF because of its role in the recruitment of CXCR4positive fibrocytes to the lung that increase the extent of fibrosis [258]. Stromal cell-derived
factor-1 (SDF-1) chemokine is a CXCR4 ligand generally secreted by bone marrow stroma
cells. However, SDF-1 also can be secreted by pulmonary fibroblasts and alveolar
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epithelial type II cells (AEC II), leading to activation and recruitment of CXCR4 positive
cells [259]. CXCR4 is abundantly expressed in IPF patients, with prominent expression in
honeycomb cysts and the distal airway epithelium [260]. CXCR4 inhibition attenuates the
progression of bleomycin (BLM)-induced pulmonary fibrosis in mice [148].
Excessive phosphorylation of a signal transducer and activator of transcription 3
(STAT3) has been implicated as a driver of aberrant fibroblast activation [261]. STAT3 is
a cytoplasmic transcription factor with important role in cell proliferation, migration,
differentiation, and survival [262]. TGF-β signaling triggers phosphorylation of JAK2, which
then interacts with and phosphorylates STAT3 to induce a fibrotic response [263]. STAT3
signaling is hyperactivated in systemic sclerosis in a TGF-β-dependent manner,
suggesting that STAT3 may be a core mediator of fibrosis. In this study, we report on the
development of PFC nanoemulsions, termed emulsion polyplexes (EPs), for pulmonary
siRNA delivery that combine CXCR4 inhibition and STAT3 gene silencing. We present
results demonstrating in vitro antifibrotic activity, favorable pulmonary biodistribution, and
the potential to reduce the severity and prolong survival in BLM-induced lung fibrosis
(Scheme 1).
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2. Materials and methods
2.1.

Materials
Fetal bovine serum (FBS), Dulbecco’s phosphate buffered saline (PBS), Dulbecco’s

modified Eagle medium (DMEM), Ham’s F-12 medium, Amphotericin B, trypsin, penicillin,
and

streptomycin

were

brought

from

Thermo

Scientific

(Waltham,

MA).

Hexamethylenebisacrylamide (HMBA) and 1-bromoheptadecafluorooctane (PFOB) were
purchased from Sigma-Aldrich. AMD3100 was from Biochempartner (Shanghai, China).
All siRNA (siScr, sense strand, 5’-UUC UCC GAA CGU GUC ACG UTT-3’; siSTAT3,
sense strand for mice, 5’-GGU CAA AUU UCC UGA GUU GUU-3’; siSTAT3, sense strand
for human, 5’-GGA GAA GCA UCG UGA GUGA-3’; carboxyfluorescein (FAM)- and Cy3labeled siRNA) and real-time (RT)-PCR primers were purchased from Sigma-Aldrich.
Curosurf® (poractant alfa) was purchased from Chiesi, Inc. (USA). Unless otherwise stated,
all other reagents were obtained from Fisher Scientific and used as received.
2.2.

Methods

2.2.1. Cells and tissues
Deidentified human primary lung fibroblasts (HPLFs), which were isolated from
patients with IPF and from non-disease control (NDC) patients, were provided through the
University of Nebraska Medical Center lung tissue biobank with prior approval from the
UNMC IRB. All HPLFs were cultured in DMEM with 10% FBS, 1% amphotericin B, 1% Lglutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37 °C in a humidified
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chamber with 5% CO2. Mouse primary lung fibroblasts (MPLFs) were isolated from the
lungs of mice with BLM-induced pulmonary fibrosis as described before [129] and cultured
at 37 °C with 5% CO2 in high-glucose DMEM with 10% FBS and Pen-Strep (100 U/mL,
100 μg/mL).
CXCR4, STAT3, col1a1, and col1a2 mRNA levels in the HPLFs and MPLFs were
measured by RT-PCR. Cells were homogenized with TRIzol reagent to isolate total RNA
following the protocol. Then the total RNA was converted into cDNA via a High-Capacity
cDNA Transcription kit. The PCR reaction was run on the Rotor-Gene Q (QIAGEN) using
iTaq Universal SYBR Green Supermix.
Deidentified human lung parenchyma slides from NDC and IPF patients were
provided by the University of Nebraska Medical Center Lung Transplant Biobank, and the
slides were sectioned and analyzed with H&E and Masson’s trichrome staining.
Immunofluorescence dual-staining for STAT3 and p-STAT3, collagen-1, and α-SMA
(smooth muscle actin) was performed, and slides observed using a confocal microscope.
2.2.2. Preparation and characterization of PAMD@PFOB/siRNA EPs
PAMD was synthesized as described previously by Michael addition of reacting 1:1
molar ratio of HMBA and AMD3100 and stirred under nitrogen in the dark at 37 °C for 3
days [264]. Excess AMD3100 was added, and the reaction was stirred for another 6 h.
The product was collected and dialyzed for 3 days against HCl acidified water (pH 3.0)
followed by final dialysis against deionized water and lyophilization. 1H-NMR in D2O
(Figure S1) using Varian INOVA (500 MHz) was used to confirm the polymer structure. To
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prepare fluorescently labeled Cy5-PAMD, Cy5-NHS ester was conjugated to PAMD in
Na2CO3/NaHCO3 buffer (pH 8.2) and kept overnight to obtain Cy5-PAMD. To prepare the
PAMD@PFOB nanoemulsion, 20 μL of PFOB was added to 2 mL PAMD (0, 0.25, 0.5, 1,
2 mg/mL) in water and ultrasonicated with a probe-type ultrasonic processor with a 2 mm
diameter (Hielscher, UP200ST) with energy limited to 8000 W under 80% output amplitude
setting.
Binding of siRNA to the PAMD@PFOB emulsion was evaluated by agarose gel
electrophoresis with 2% agarose gel containing 0.5 μg/mL of ethidium bromide.
PAMD@PFOB/siRNA EPs were formed by adding a different volume of emulsion to an
siRNA solution to achieve the desired w/w ratio, incubated at room temperature for 30
min, and run in 0.5x Tris/borate/EDTA buffer for 15 min at 110 mV. The gels were imaged
under UV with a KODAK Gel logic 100 imaging system. Hydrodynamic diameter and zeta
potential of the EPs were measured by using NanoBrook Omni (Brookhaven Instruments,
Holtsville, NY, USA). EPs morphology was analyzed using TEM (Tecnai G2 Spirit, FEI
Company, USA) with NanoVan negative staining (Nanoprobes, USA). The colloidal
stability of the emulsions in PBS was tested by measuring particle size after incubation at
4, 25, and 39 °C for 1-48 h.
2.2.3. Stability of EPs in mucus
A mucus stability assay with naked siRNA, PAMD/siRNA, and PAMD@PFOB/siRNA
(w/w = 4) EPs was evaluated via agarose gel electrophoresis. Naked siRNA, PAMD/siRNA,
and EPs (w/w = 4, 0.2 μg siRNA) were incubated at 37 °C with 10% mucus (diluted in

57

PBS) obtained from patients with chronic obstructive pulmonary disease (COPD). We
collected the samples at predetermined time points. Heparin (80 μg/mL) was used to
release siRNA, then analyzed by gel electrophoresis. FRET was also used to measure
the mucus and pulmonary surfactant stability of EPs against disassembly. Cy5PAMD@PFOB/Cy3-siRNA (w/w = 4) were prepared using the same methods as
described above, and EPs containing 5 μg Cy3-siRNA were incubated with the 10%
mucus obtained from COPD patients (2 mL) or 20% of Curosurf® (pulmonary surfactant)
for 5 h, and 24 h at 37 °C. The fluorescence intensity at 667 and 568 nm upon excitation
at 550 nm was measured by recording the fluorescence emission spectra according to an
earlier report [231].
A heparin displacement assay was performed to analyze siRNA release from EPs.
PAMD@PFOB/siRNA EPs (w/w = 4) were incubated with different concentrations of a
heparin solution for 30 min, then assayed by gel electrophoresis. SYBR-Safe was used to
evaluate the amount of released siRNA. EPs with 0.2 μg siRNA were prepared in HEPES
buffer, and 100 μL of each EP solution was distributed in a white 96-well plate. 3 μL 40x
SYBR safe was added to each well and incubated for 10 min in the dark. Fluorescence
was measured by a SpectraMax iD3 plate reader microplate reader (Molecular Devices,
CA) at 500 nm excitation and 555 nm emission wavelengths. An analogous procedure
with free siRNA was used and set as 100%.
To evaluate the PAMD@PFOB/siRNA-mucus interactions, the EPs (w/w = 4, 5 μg
siRNA) were mixed with mucus solution (0.3% or 0.5% mucus and diluted in PBS, 2 mL)
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and incubated for 5 h at 37 °C. The mixture was centrifuged for 2 min. Then, the
precipitates were washed with PBS and treated with NaOH (5 M, 200 μL) for 10 min, and
the fluorescence intensity was measured by SpectraMax iD3 plate reader (Ex = 550 nm,
Em = 565 nm) [231].
Multiple particle tracking was used to evaluate the trajectory of particles in the mucus.
Briefly, PAMD@PFOB/siRNA or PAMD/siRNA were mixed with COPD mucus (1 mL) and
transferred to 1 mL syringe. After equilibration for 1 h at room temperature, 20 s videos of
particle movement and particle trajectories were captured using NanoSight (NS300).
ImageJ software (Fuji) was used to convert particle movement into metric displacement in
both the X and Y directions. The mean square displacement (MSD) was determined as
(X∆t)2 + (Y∆t)2.
2.2.4. Cytotoxicity of PAMD@PFOB emulsion in HPLFs and MPFLs
Cytotoxicity of PAMD@PFOB emulsion was tested via a CellTiter-Blue Cell (CTB)
Viability Assay (Promega, WI). Cells were seeded onto 96-well plates at 6,000 cells per
well, then, after 12-18 h, the cells were treated with a 100 μL of emulsion with increasing
concentrations in culture medium for 24 and 48 h. Then, cell viability was evaluated by the
CTB reagent according to the manufacture recommendations. The half-inhibitory IC50
values were calculated from a dose-response analysis in GraphPad Prism.
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2.2.5. Fibroblast proliferation and migration
The in vitro cell proliferation assay was evaluated by CTB assay. The HPLFs were
seeded in a 96-well plate (6,000 cells per well). After 18 h, the cells were treated with EPs
(w/w = 4, siRNA 100 nM) using serum free medium. The medium was replaced after 4 h
with medium containing 10% FBS for another 48 h. Cell viability was then measured using
CTB assay according to the manufacturer’s recommendations. NDC HPLFs treated with
PBS served as a negative control and IPF HPLFs treated with PBS served as a positive
control.
The Transwell migration assay was conducted as previously described.[265] For
comparison of migration between NDC and IPF HPLFs, the cells were detached and
washed with PBS, then re-suspended in serum free medium (1x104, 2x104, 4x104, and
6x104 cells in 300 μL medium per insert, 8.0 μm pores). 600 μL medium with 10% FBS
was added into the lower transwell chamber. After 16 h of incubation, the non-migrated
cells in the top chamber were removed. Migrated cells at the bottom were fixed and stained
with 0.2% Crystal Violet. The migrated cells were observed and counted under EVOS xl
microscope.
The effect of PAMD@PFOB/siSTAT3 EPs on the myofibroblast migration was
evaluated with IPF HPLFs. Cells were detached and washed with PBS, then resuspended
in serum free medium. Cells were pretreated with EPs or polyplexes (without emulsion)
for 30 min, and 300 μL of serum-free medium (4x104 cells per insert) was added into the
cell culture inserts. 600 μL medium with 10% FBS was added into the lower transwell
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chamber. After 16 h incubation, the non-migrated cells in the top chamber were removed.
Migrant cells were fixed and stained with 0.2% Crystal Violet. The migrated cells were
observed and counted under EVOS xl imaging system. NDC HPLFs treated with PBS
served as a negative control, and IPF HPLFs treated with PBS served as a positive control.
Results were interpreted as the percentage of migrated cells relative to NDC HPLFs (n =
3).
2.2.6. Cellular uptake and intracellular tracking
HPLFs and MPLFs were seeded in 12-well plates and adhered overnight before
treatment. Cells were then treated with PAMD/FAM-siRNA or PAMD@PFOB/FAM-siRNA
(w/w = 4, 100 nM FAM-siRNA) for 4 h. Cells were washed with PBS, detached, and
analyzed by flow cytometry. Subcellular distribution of nanoparticles was observed by
confocal microscopy. Cells were seeded in confocal dishes 24 h before the treatment.
Cells were then treated with PAMD@PFOB/Cy5.5-siRNA EPs. After 4 h, cells were
washed with PBS, stained with Hoechst 33324, and visualized under confocal microscopy
(LSM 710, Zeiss, Jena, Germany). To investigate the endosome siRNA escape, HPLFs
(IPF) were treated by Cy3-PAMD@PFOB/Cy5.5-siRNA. After 4 h incubation, cells were
washed with PBS, stained with LysoView (green) and Hoechst 33324, and visualized with
confocal microscopy.
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2.2.7. Pulmonary distribution of EPs in pulmonary fibrosis mice
All animal experiment protocols were approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee. Male C57BL/6 mice were injected
intraperitoneally with BLM (twice per week, 4 weeks, 30 U/kg) to induce pulmonary fibrosis.
On day 28, mice were intratracheally administered 40 μL of EPs prepared with Cy5-PAMD
and FAM-siRNA (15 μg siRNA per mouse, w/w = 4). At different times post-treatment (1
h, 5 h, and 24 h after the treatment), whole body fluorescence imaging was conducted
prior to ex vivo analysis of the fluorescence in individual organs using Xenogen IVIS 200.
Lungs were collected, inflated with O.C.T compound to ensure embedded, cut into frozen
sections (10 μm), nuclei stained with DAPI, and then imaged by confocal microscopy.
2.2.8. Ciliary beat frequency (CBF) [266]
After 4 weeks of treatment with BLM, C57BL/6J male mice were euthanized, the
trachea was extracted and opened lengthwise, then placed in protease solution (1.5
mg/mL) for 18-24 h. The tracheas were then discarded, and the solutions were centrifuged
(200 x g) to get the mouse tracheal epithelial cells (MTECs). Then cells were plated onto
an uncoated polystyrene plastic culture dish in MTEC basic media with 10% FBS [MTEC
basic media consists of a 1:1 solution of Ham’s F-12 and DMEM supplemented with
Pen/Strep (1%), amphotericin B (250 μg/mL), gentamicin (40 mg/mL), and glutamine (4
mM)]. Due to the differential adherence property of MTECs, after 4 h incubation, the
adhered fibroblasts were removed, then washed and counted the MTECs. MTECs were
seeded on inserts with Type I collagen-coated membrane and grown in MTEC
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supplementary media [consists of basic media supplemented with 0.1% insulin, 0.1%
transferrin, 0.1% Epidermal Growth Factor (EGF), 0.4% Bovine Pituitary Extract (BPE),
0.1% cholera toxin (CT), 0.001% retinoic acid (RA), and 5% FBS]. By the 6th day, the cells
were cultured at air-liquid interface (ALI).[266] After 14-21 days at ALI, a baseline CBF
reading was measured, and the cells were treated with 100 μL of EPs or polyplexes (w/w
= 4, siRNA = 100 nM). After 48 h, the beating cilia were observed using an inverted phasecontrast microscopy, and CBF was calculated using the Sisson Ammons Video Analysis
(SAVA) method [267].
2.2.9. Anti-fibrosis activity of EPs in vivo
Pulmonary fibrosis was induced in C57BL/6 mice as stated previously; however, on
day 14, mice were randomly assigned to four intratracheal treatment groups: PBS,
PAMD/siSTAT3, PAMD@PFOB/siScr, and PAMD@PFOB/siSTAT3 (w/w = 4, 40 μL, 15
μg siRNA/mouse). The mice were administered treatment on days 14, 17, 20, 23, and 26.
Untreated C57BL/6 mice served as controls. Mouse body weight was recorded during the
entire process. At day 30, bronchoalveolar lavage fluid (BALF) from three mice of each
group was collected, centrifuged for 10 min at (300 x g) at 4 °C, the cell pellets were resuspended in 200 μL PBS, and total cell number enumerated. All mice were euthanized
at day 30 and lung tissues were inflated with 400-800 μL formalin and harvested for the
histological and biomedical analyses. The pulmonary edema was evaluated by measuring
the wet/dry (W/D) weight ratio. The lungs were excised, washed with PBS, and weighed
to acquire the wet weight. Then, lung tissue was dried at 65 °C for 3 days to acquire the
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dry weight and the W/D weight ratio was calculated. STAT3, CXCR4, and connective
tissue growth factor (CTGF) mRNA levels in the lung were measured by RT-PCR. Lungs
were homogenized with TRIzol reagent to isolate total RNA following the protocol. Then
the total RNA was converted into cDNA via a High-Capacity cDNA Transcription kit. The
PCR reaction was run on the Rotor-Gene Q (QIAGEN) using iTaq Universal SYBR Green
Supermix. Hydroxyproline (HYP) levels in the lung tissues were measured according to
the protocol of the Hydroxyproline Assay Kit (Abcam, US). A 60-day survival study was
also performed with the same treatment regimens previously stated using 8 mice per
group.
2.2.10. Immunohistochemical analysis
IPF HPLFs were seeded in an 8-well chambered for 24 h before treatment. The cells
were then treated by PAMD@PFOB/siRNA EPs or polyplexes (w/w = 4, 100 nM siSTAT3)
in serum-free medium. After 4 h incubation, replace with fresh medium containing 10%
FBS for another 48 h. Cells were fixed for 15 min, blocked with 5% bovine serum albumin
and 0.2% Triton X-100 for 1 h. The cells were incubated with α-SMA primary antibody
(1:200) at 4 °C overnight. Then, the cells were rinsed three times in PBS for 5 min each
and incubated with anti-rabbit IgG AlexaFluor 488 secondary antibody (Thermo Fisher)
for 1 h at room temperature. Hoechst 33324 was used to stain nuclei for 15 min and
imaged by confocal microscopy. NDC HPLFs treated with PBS served as negative
controls and IPF HPLFs treated with PBS served as positive controls.
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Mouse lung tissues obtained from the treatment groups were inflated and fixed in 4%
paraformaldehyde and then stored in 75% ethanol. Then, the lung tissues were embedded
in paraffin and sectioned for histochemical analysis with H&E and Masson’s trichrome
staining. Immunohistochemical (IHC) staining for CXCR4 was conducted in tandem with
immunofluorescence (IF) dual-staining for STAT3 and p-STAT3, collagen-1 and α-SMA.
Lung slides were deparaffinized and treated with endogenous peroxidase inhibitor, then
block slides for 10 min with blocking solution, followed by incubating with primary
antibodies at 37 °C for 32 min. The slides were rinsed in IF buffer 3 times for 5 min each,
then incubated with the Discovery Cy5 or Cy3 Kit. Slides were also counterstained for 5
min with DAPI and then evaluated using confocal microscopy (LSM 710). IHC images
were obtained by the EVOS xl microscope (Thermo, US).
2.2.11. Statistical analysis
Results are presented as mean ± SD. Total sample size (n) was given for each
experiment as follows: in vitro study (n = 3-6); in vivo biodistribution study (n = 3); in vivo
therapeutic study (n = 10); survival study (n = 8); H&E staining, Masson’s trichrome
staining, immunochemistry staining, and immunofluorescence staining (n = 3-6). One-way
ANOVA test with Tukey’s multiple comparisons test was used to analyze differences
among multiple groups followed by a comparison test. Student’s t-test was used to analyze
the statistical significance between two groups, and differences were assessed to be
significant. In all the case, P-value < 0.05 were considered statistically significant, and
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significance was indicated as *p<0.05 or #p<0.05, **p<0.01 or ##p<0.01, and ***p<0.001
or ###p<0.001. All the statistical analysis was performed with GraphPad Prism 8.
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3. Results and discussion
Our group previously demonstrated pulmonary administration of EPs with effective
lung distribution and therapeutic efficiency [147, 148]. Here, we further optimized the EPs
formulation by developing PFOB nanoemulsions to improve delivery of polycation/siRNA
polyplexes to treat pulmonary fibrosis in a BLM-induced small animal model [268]. This
novel approach relies upon creating positively charged PFOB nanoemulsions that can
bind and deliver siRNA. When combined with stabilizing polycations that function as
inhibitors of CXCR4, the resulting delivery system offers a unique two-pronged small
molecule and siRNA strategy for inhalation therapy to reduce pulmonary fibrosis.
3.1.

Physiochemical characterization of PAMD@PFOB/siRNA EPs
We have developed CXCR4-inhibiting polycations, named PAMD, that form

nanosized polyplexes with nucleic acids, such as siRNA, miRNA, and DNA [264, 269273]. In this study, we have used PAMD as a surfactant to stabilize PFOB nanoemulsions
and to form EPs to improve the pulmonary siRNA delivery in mice with pulmonary fibrosis.
We synthesized PAMD with a weight-average molecular weight of 10 kDa and its 1H-NMR
spectrum is shown in Figure 2.1. PAMD@PFOB (o/w) emulsions were prepared via a onestep ultrasonication method [252] using 1% v/v PFOB in the presence of different
concentrations of PAMD (Figure 2.2A). The emulsion consisted of the PFOB core and the
stabilizing PAMD shell (Figure 2.2B). The structure enabled exposure of the CXCR4binding moieties in PAMD on the surface of the emulsion while providing the positive
surface charge needed for siRNA binding. The PAMD@PFOB emulsions remained
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relatively stable for at least three days at room temperature as indicated by a particle size
increase of less than 20% (Figure 2.2C). As shown in Figure 2.2D, even the lowest tested
concentration of PAMD (0.25 mg/mL) was sufficient to stabilize the PFOB emulsion and
limit particle size growth. The particle size of the PAMD@PFOB emulsion prepared with
2 mg/mL PAMD was 175 ± 2 nm and the zeta potential was 20.5 ± 0.9 mV (Figure 2.2A&F).
The ability of siRNA to bind to PAMD@PFOB emulsions was then evaluated by a gel
retardation assay (Figure 2.2E). The EPs were prepared by mixing increasing amounts of
PAMD@PFOB emulsion with siRNA solution. We found that siRNA bound completely to
the emulsion at a w/w ratio of PAMD/siRNA (excluding PFOB) above 2. We used w/w=4
in subsequent in vitro and in vivo studies to maintain slight excess of CXCR4-binding
moieties not engaged in electrostatic interactions with siRNA. The EPs that were prepared
at w/w=4 had a size of ~190 nm and the zeta potential was ~19 mV (Figure 2.2E). The
residual positive zeta potential confirmed that some CXCR4 binding moieties likely
remained presented on the surface of the emulsion despite siRNA binding. CXCR4
antagonism of PAMD@PFOB emulsion was validated using a CXCR4 receptor
redistribution assay (Figure 2.3). Both PAMD and PAMD@PFOB displayed dose
dependent CXCR4 antagonism.
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emulsion polyplexes. (A) Particle size distribution of PAMD@PFOB emulsion. (B)
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3.2.

Cytosolic siRNA delivery and anti-fibrotic effect of EPs in primary mouse
and human lung fibroblasts
We first assessed the toxicity of EPs in mouse primary lung fibroblasts (MPLFs) that

were isolated from lungs with established fibrosis [MPLFs (IPF)], as well as human primary
lung fibroblasts (HPLFs) isolated from IPF patients [HPLFs (IPF)] and non-disease control
[HPLFs (NDC)] (Figure 2.4). MPLFs (IPF) exhibited less cytotoxicity in response to PAMD
and EPs than both NDC and IPF HPLFs. No significant cytotoxicity was observed with the
EPs formulations used at a w/w ratio of 4 and 100 nM siRNA, and these were thus used
in subsequent studies. Based on prior studies, we hypothesized that the localization of the
PAMD and siRNA on the surface of the PFOB nanoemulsions would improve siRNA
cytosolic delivery. EPs were prepared with fluorescently labeled siRNA and cell
internalization in the HPLFs (IPF, Figure 2.5A) and MPLFs (IPF, Figure 2.5B) was
examined

by

confocal

microscopy

and

flow

cytometry.

We

found

that

PAMD@PFOB/siRNA EPs significantly improved siRNA cellular uptake when compared
with the PAMD/siRNA in both the human primary and mouse primary fibroblasts obtained
from fibrotic lungs. This result was also confirmed by flow cytometry. Endosomal escape
of the PAMD@PFOB/siRNA EPs in HPLF (IPF) was evaluated using LysoView to stain
lysosomes. After 4 h incubation, Cy5.5-siRNA was found mostly in the cytoplasm with only
a small amount present in the lysosomes as suggested by the limited overlap with the
LysoView signal (Figure 2.5C). These results suggested that PFOB nanoemulsion can
enhance the cytosolic siRNA delivery. However, the mechanism governing this process is
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poorly understood. The cellular uptake and endosome escape results showed that most
siRNA could escape from the lysosomes and be transported to the cytosol, which
suggested that the mechanism may involve the perturbation of intracellular phospholipid
membranes.[274] Further studies need to be performed to gain better understanding.
Differentiated fibroblasts play a key role in the progression of IPF and strategies that
modulate their function may have a significant impact on the treatment of IPF.[275] The
characteristic differential expression of cytoskeletal proteins such as α smooth muscle
actin (α-SMA) can be used as a marker of activated lung myofibroblasts. We evaluated
expression of α-SMA in IPF and NDC HPLFs and determined the effect of treatment with
EPs (Figure 2.5D). As expected, the IPF HPLFs showed higher expression of than HPLFs
(NDC), and treatment with PAMD@PFOB/siSTAT3 EPs significantly decreased the αSMA expression. Control treatment with EPs prepared with scrambled siRNA and
polyplexes without the PFOB emulsion showed a less pronounced effect on α-SMA
expression. Fibroblasts in IPF lungs represent a population of cells with diverse
phenotypes and functions. The accumulation of fibroblasts and myofibroblasts is a
hallmark of IPF, leading to the production of excessive ECM [276]. Activated
myofibroblasts can induce apoptosis of epithelial cells, which contributes to the absence
of re-epithelialization and thereby perpetuating IPF [277, 278]. Activated fibroblasts from
IPF can be also distinguished by increased migration as confirmed in Figure 2.6A when
compared with NDC HPLFs. CXCR4, STAT3, col1a1, and col1a2 expression were
significantly elevated in IPF HPLFs when compared with NDC HPLFs (Figure 2.6B,C).
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Importantly, when treating the IPF HPLFs with the PAMD@PFOB/siSTAT3 EPs, the
expression of STAT3, col1a1, and col1a2 decreased and reached the levels similar to the
control HPLF (NDC) (Figure 2.6C). We also examined the role of CXCR4 and STAT3
inhibition in fibroblast proliferation and migration (Figure 2.5E,F). IPF HPLFs were treated
with PAMD/siSTAT3, PAMD@PFOB/siScr, and PAMD@PFOB/siSTAT3. All the used
treatment were capable of CXCR4 inhibition and achieved nearly complete inhibition of
cell migration, similar to NDC HPLFs. Moreover, treating the HPLFs (IPF) with
PAMD@PFOB/siSTAT3 resulted in better migration inhibition than treatments with
PAMD/siSTAT3 and PAMD@PFOB/siScr. Fibroblast proliferation experiments showed
similar results in that the IPF HPLFs displayed significantly increased proliferation (Figure
2.5F). To further confirm that proliferation of fibroblasts requires CXCR4 and STAT3
activation, we treated cells with PAMD@PFOB/siSTAT3 EPs. As shown in Figure 3F,
PAMD@PFOB/siSTAT3 EPs significantly suppressed fibroblasts proliferation. We also
evaluated the STAT3 gene silencing efficacy in the HPLFs IPF, siRNA cell uptake was
improved significantly by the EPs and resulted in improved STAT3 gene silencing efficacy
(Figure 2.5G).
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3.3.

Enhanced mucus stability and penetration and decreased CBF by EPs
Efficient pulmonary delivery of siRNA is a complex process that demands sufficient

stability of the delivery system to reach the desired location in the lungs. The mucus that
covers the airway epithelium is a major obstacle to pulmonary siRNA delivery in addition
to other host defense factors that capture the particles and eliminate them from the lungs
[279].
As part of comprehensive stability testing, a heparin displacement assay was first
used to evaluate the resistance against polyelectrolyte exchange causing the release of
siRNA from EPs. As shown in Figure 2.7, siRNA was completely released from the EPs

% of Free siRNA

when the heparin concentration was above 80 μg/mL indicative of good stability.
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Figure 2.7 Physicochemical characterization of PAMD@PFOB/siRNA EPs. (A) Heparin
induced siRNA release from PAMD@PFOB/siRNA emulsion polyplexes (w/w=4) with
increasing heparin concentration.

Stability and penetration of the fluorescently labeled nanoemulsions (Cy5-PAMD/Cy3siRNA) were probed in mucus obtained from patients with chronic obstructive pulmonary
disease (COPD) using fluorescence resonance energy transfer (FRET) by labeling
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separate batches of EPs with Cy3-siRNA and Cy5-PAMD (a known FRET couple).[280]
As shown in Figure 2.8A, after 24 h of coincubation with mucus, a significant decrease in
FRET signal (fluorescence intensity at 667 nm upon excitation at 550 nm) was exclusively
observed for the PAMD-Cy5/Cy3-siRNA group, suggesting disassembly of the polyplexes.
After 24 h in 10% mucus, the EPs were more stable, whereas the FRET changes in case
of polyplexes (PAMD-Cy5/Cy3-siRNA) suggested that there were almost no remaining
particles at 24 h. Thus, the PAMD@PFOB/siRNA EPs remained more stable in mucus
and prevented undesired dissociation and siRNA release. Aggregation in mucus may also
contribute to poor delivery and limit efficacy of the particles. Therefore, adsorption of mucin
to EPs was investigated by quantitating the amount of EP/mucin aggregates (Figure 2.8B).
In this assay, higher fluorescence intensity corresponds to increased formation of the
particle/mucin aggregates. After 5 h in mucus, the fluorescence intensity of the
PAMD/Cy3-siRNA group was higher than the PAMD@PFOB/Cy3-siRNA EPs group,
suggesting more of the polyplex/mucin aggregation than the EPs/mucin, proving that the
EPs aggregated significantly less than the control PAMD/siRNA polyplexes both in 0.3%
and 0.5% mucus.
Mucus penetration properties of PAMD@PFOB/siRNA EPs were evaluated using
NanoSight to track the trajectories of the nanoparticles in mucus. As shown in Figure 2.8C,
the movement of PAMD/siRNA polyplexes in the mucus was severely impeded when
compared with the movement in water. However, the movement of PAMD@PFOB/siRNA
EPs in the mucus remained high. Importantly, the geometric averaged mean square
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displacement (MSD) values for PAMD@PFOB/siRNA also remained relatively stable
when compared with the MSD values for PAMD@PFOB/siRNA in water. In contrast, the
MSD of PAMD/siRNA decreased significantly when compared with the water. Both mucus
and pulmonary surfactant are important in defining the fate of the materials in the lung.
We thus evaluated the effect of porcine pulmonary surfactant (Curosurf®) on the stability
of PAMD@PFOB/siRNA EPs (Figure 2.9). Using FRET, agarose gel, and TEM showed
that PAMD@PFOB/siRNA EPs retained their integrity and remained stable in the
presence of pulmonary surfactant.
We evaluated the influence of EPs treatment on ciliary beat frequency (CBF). The cilia
were assayed by measuring the average number of motile points in multiple whole field
measurements of the mouse tracheal epithelial cells (MTEC) grown at an air-liquid
interface (ALI) (Figure 2.8D). Treating the MTEC with PBS did not significantly change
CBF. In contrast, there was a decrease in CBF compared to the PBS group when MTEC
were treated with PAMD@PFOB/siSTAT3. Because particle stimulation of cilia is a wellestablished concept,[281] this result may point to benefits for the inhalation of EPs as it
may decrease the extent of their clearance. The mechanism of PAMD@PFOB/siSTAT3
influence on the CBF in MTEC may involve silencing STAT3 expression but this requires
further investigation.
The siRNA stability in the EPs in mucus was also evaluated via agarose gel
electrophoresis (Figure 2.8E). Compared with free siRNA and PAMD/siRNA,
PAMD@PFOB/siRNA EPs were better at protecting siRNA from mucus-induced
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degradation. Moreover, in agreement with the above in vitro studies that demonstrated
enhanced mucus and pulmonary surfactant stability and decreased CBFs by EPs, the
histological results showed that the distribution of PAMD/siRNA polyplexes was confined
to the mucus layer of the airways with extremely limited penetration to the deeper areas
of the lung (Figure 4F). In contrast, the EPs could efficiently permeate through the mucus
layer and penetrate into deeper regions of the lung. We contend that unlike most PFCs,
PFOBs has less lipophilicity due to the bromine atom in its structure [282]. This may in
turn decrease the interaction between EPs and negatively charged mucin glycoproteins,
which may help with mucus penetration.
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3.4.

Histology analysis of the lungs from IPF patients and mice with pulmonary
fibrosis
Figure 2.10A&B shows H&E and Masson’s trichrome stained slides from IPF patients

and mice with BLM-induced pulmonary fibrosis together with healthy controls. As shown
in Figure 2.10A, healthy lung (NDC) appeared normal with intact alveolar size and
structure. As expected, IPF patient samples revealed dense thickening of the lung
parenchyma, displacement and damage to the alveolar walls, and perivascular fibrosis
was evident. Similar results were also found in the mice with BLM-induced pulmonary
fibrosis, validating that the animal model mimics the human disease (Figure 2.9B).
Masson’s trichrome staining also revealed large amounts of collagen deposition in the IPF
patient lungs compared to NDC, as confirmed by increased immunostaining of collagen I
and α-SMA (Figure 2.10C-E). Collagen I (red) and α-SMA (green) staining was
significantly more abundant in IPF than in NDC lung sections.
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Figure 2.10 Histology analysis of the lungs from IPF patients compared with NDC, and
BLM-induced pulmonary fibrosis mice (Day 35) compared with healthy (Day 0) control.
(A) H&E and Masson staining of the human samples. (IPF patients compared with the
NDC). (B) H&E and Masson staining of lungs from BLM-induced pulmonary fibrosis mice
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for collagen I (red) and α-SMA (green) co-stained with DAPI (blue). (D) Quantitative
analysis of IF staining for collagen I. (E) Quantitative analysis of IF staining for α-SMA.
4X: Scale bar = 1000 μm. 20X: scale bar = 200 μm.
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STAT3 expression and activation were analyzed by quantifying the extent of
phosphorylation at tyrosine 705 (p-STAT3), a marker for STAT3 activation. Consistent
with α-SMA and collagen I expression, increased p-STAT3 and total STAT3 were
observed in the parenchyma of IPF patient samples (P<0.0005 vs NDC), whereas only a
few cells were positive for p-STAT3 in healthy individuals (NDC, Figure 2.11A-C). The
activation of STAT3 signaling in mice with pulmonary fibrosis was also evaluated in
experimental models of BLM-induced pulmonary fibrosis in mice (Figure 2.11D-F).
Establishing pulmonary fibrosis by repeated intraperitoneal injection of BLM (30 U/kg) into
mice significantly increased p-STAT3 and total STAT3 as compared to control mice.
Increased STAT3 signaling was detected after 4 injections of BLM (2 weeks after first
injection) and persisted throughout the transition to established fibrosis.
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3.5.

Improved siRNA pulmonary delivery by EPs
We used a lung fibrosis model based on repeated intraperitoneal injection of BLM in

C57BL/6 mice. This model mimics human disease with similar lung pathology, including
injury and activation of epithelial cells and inflammatory cell infiltrates, the production of
proliferation factors, collagen deposition, and parenchymal consolidation [283]. The model
progresses through the following three stages: (1) acute injury and inflammation phase
(day 1-12) that is characterized by an influx of inflammatory cells and upregulation of
proinflammatory cytokines and chemokines; (2) the transition phase from inflammation to
active fibrosis (day 12-24), which shows gradual subsiding of the inflammatory response
with an accompanying increase in fibroproliferation, myofibroblast emergence, and
increase in the expression of α-SMA, collagen I, CXCR4, STAT3, and p-STAT3 (Figure
2.12&2.13); and (3) the established chronic fibrosis stage (day 25-42), which is
characterized by the expansion of the myofibroblast population and substantial deposition
of ECM.
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Figure 2.12 Representative image of BLM-induced pulmonary fibrosis mice. (A) Timeline.
(B) Representative images of the histopathological examination of the lung sections with
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fibrosis mice. 4X: Scale bar = 1000 μm. 20X: scale bar = 200 μm. (C) Activation of the
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Figure 2.13 Accumulation of collagen I deposition and expression of α-SMA in BLMinduced IPF mice (male and female). Representative image of IF staining for collagen I
(red) and α-SMA (green) co-stained with DAPI (staining of nuclei) (A&B: male mice. C&D:
female mice. A&C: 40x, scale bar=100 μm. B&D: 63x, scale bar= 60 μm). Quantitative
analysis of IF staining for α-SMA (E) and collagen I (F).
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We first evaluated the biodistribution of EPs at the different stages of BLM-induced
pulmonary fibrosis (Figure 2.14). Using dual labeled EPs (Cy5-PAMD@PFOB/FAMsiRNA) that were instilled intratracheally (40 μL, 15 μg siRNA per mouse), the
biodistribution was determined 5 h post-administration using whole-body imaging and ex
vivo imaging of lungs and other major organs. The results showed optimal EPs
accumulation during the second stage of fibrosis when the transition from inflammation to
active fibrosis occurs. The lung clearance in healthy mice was faster than in mice with
established pulmonary fibrosis (Figure 2.14B,D). Importantly, EPs penetrated throughout
the entire lung, even at stage 3 where extensive collagen and ECM deposition is present
(Figure 2.14E). From these results, we conclude that PFOB enhances mucus penetration
of polycationic vectors in vivo.
Lung deposition and penetration were further evaluated in detail at established
fibrotic mice lungs. Cy5-PAMD@PFOB/FAM-siRNA (40 μL, w/w = 4, siRNA 15 μg per
mice) or Cy5-PAMD/FAM-siRNA polyplexes were intratracheally instilled. Following this,
the animals were sacrificed at 1 h, 5 h, and 24 h, and fluorescence imaging of the whole
body and major organs was performed (Figure 2.15). At 5 h post treatment, the mice
administered EPs had the highest lung accumulation, most likely due to better mucus
stability and penetration of EPs than the simple polyplexes without PFOB emulsion. The
Cy5-PAMD/FAM-siRNA polyplexes were largely trapped in the mucus layer and cleared;
thus, unable to diffuse into deeper regions of the lung. The fluorescent signal was
remained localized in the lung and not found in the other organs within 24 h post instillation.
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To further explore the extent of penetration into the lung tissue, the intra-lung
distribution of labeled EPs was evaluated via confocal microscopy. Lungs were collected,
inflated with OCT, and embedded for frozen tissue sectioning (Figure 2.15D). Both Cy5PAMD (red) and FAM-siRNA (green) fluorescence colocalized in the lungs, suggesting
that the EP integrity was retained during the delivery phase. We were also able to
demonstrate that EPs penetrated into lower lobes as early as 1 h post administration and
spread to all lobes within 5 hours.
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3.6.

Therapeutic efficacy of EPs in BLM-Induced pulmonary fibrosis mice
Next, we evaluated the anti-fibrotic efficiency of PAMD@PFOB/siSTAT3 in vivo. EPs

(15 μg siRNA per mouse) were intratracheally instilled on day 14 and continued every 3
days for a total 5 doses (Figure 2.16A). Histopathological analysis of isolated lungs from
the untreated fibrosis group showed loss of normal alveolar appearance and thickening of
the alveolar wall (Figure 2.16B). Increased airway exudate (edema) was also observed.
Treatment with PAMD@PFOB/siSTAT3 notably alleviated tissue damage, including
interstitial edema and thickening of the alveolar wall (Figure 2.16B). Histopathological
scores were assigned to the lung tissue sections in a blinded manner by a pathologist
(Figure 2.16C) using the following scale: 1 = normal lung, 2 = mild inflammation, 3 =
moderate inflammation, 4 = obvious inflammation, 5 = severe inflammation. As expected,
the untreated (BLM+PBS) group showed severe inflammation and the treatment with
PAMD@PFOB/siSTAT3 decreased the pathology score significantly.
Pulmonary collagen deposition was evaluated by Masson’s trichrome staining (Figure
2.16B, blue area) and a HYP assay (Figure 2.16D). The untreated fibrosis group showed
5.7

times

more

collagen

deposition

than

healthy

mice.

Treatment

with

PAMD@PFOB/siSTAT3 EPs decreased collagen content by ~50% when compared to
untreated controls. This result is consistent with the inhibition of activation and migration
of HPLFs and suggests that PAMD@PFOB/siSTAT3 EPs reduce activation and
proliferation of fibroblasts and decrease ECM production via combined CXCR4 inhibition
and STAT3 silencing. Therefore, combined inhibition of CXCR4 and STAT3 gene silencing
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is protective in BLM-induced pulmonary fibrosis as shown by the reduced alveolar wall
thickening, fibroblast proliferation and migration, myofibroblast differentiation, and HYP
content.
Immunohistochemical staining of lung sections and RT-PCR were performed to
measure CXCR4 lung expression (Figure 2.16B,E). The lungs of animals treated with the
PAMD@PFOB/siSTAT3 showed the lowest levels of CXCR4 expression because of the
inhibition of fibroblast differentiating into myofibroblast as well as inhibition of CXCR4+
fibrocyte recruitment from the bone marrow to fibrotic lung tissue. We contend that due to
improved mucus penetration, EPs had superior ability to inhibit CXCR4 expression in vivo
when compared to control polyplexes. Pulmonary edema is also an indicator of lung
fibrosis [284] and can be estimated by the W/D ratio (Figure 2.16F). The lungs of untreated
fibrotic mice had an increased W/D ratio compared to healthy mice. Strikingly, W/D ratios
decreased as a result of EPs treatment in comparison to control polyplexes. Consistent
with this the total number of cells in BALF, an indicator of inflammatory cell infiltration was
significantly decreased following PAMD@PFOB/siSTAT3 treatment (Figure 2.16G).
Severe loss of body weight was observed in the untreated fibrosis group (BLM+PBS)
(Figure 2.16H), while weight loss in the PAMD@PFOB/siSTAT3 treatment group was less
severe.
We next determined whether PAMD@PFOB/siSTAT3 treatment improved survival.
PAMD@PFOB/siSTAT3 treatment extended mean survival to 52 days when compared to
animals that received no treatment (Figure 2.16I). H&E and Masson’s staining of the lungs
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from two mice that survived out to 60 days show that EPs treatment prolonged survival
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and attenuated fibrotic progression (Figure 2.17).

EPs-2

Masson

H&E

EPs-1

3 mm

Figure 2.17. Representative images of the histopathological examination of the lung
sections with H&E, Masson’s staining of 2 mice who survived at day 60 at
PAMD@PFOB/siSTAT3 EPs group.
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The extent of p-STAT3 and total STAT3 expression was also assessed by IF staining
and RT-PCR and images were further analyzed by ImageJ (Figure 2.18A-D). The
untreated group had significantly increased expression of all markers whereas,
PAMD@PFOB/siSTAT3 EPs treatment silenced STAT3 expression and reduced
activation. The representative images of IF staining of collagen I and a-SMA, co-stained
with DAPI, are shown in Figure 2.18E with quantification in Figure 2.18F (a-SMA) and
Figure 2.18G (collagen I). Collectively, PAMD@PFOB/siSTAT3 treatment decreased
ECM production. Moreover, Evaluation of the CTGF mRNA levels in the lung showed
significantly elevated CTGF expression in the untreated mice (Figure 2.18H). Treatment
with PAMD@PFOB/siSTAT3 EPs attenuated the CTGF expression.
Previously, studies proved that control of STAT3 signaling by pharmacological
methods inhibited TGF-β-dependent fibroblast activation and ameliorated experimental
fibrosis in murine models. Mice with conditional deletion of STAT3 in fibroblasts are
protected from skin fibrosis [285]. As a result of epithelial damage in IPF, alveolar epithelial
cells undergo apoptosis and epithelial-mesenchymal transition to provide mesenchymal
cells for the initial repair process [286]. Residual lung fibroblasts in the interstitium start to
proliferate and migrate to the site of injury, leading to excessive fibroblast proliferation,
migration, and transformation to myofibroblast, as well as synthesis and deposition of
ECM [244]. Moreover, CXCR4/SDF-1 and STAT3 signaling interferes with fibroblasts to
myofibroblast proliferation and migration. Here, we developed PFOB EPs, combining the
properties of CXCR4 attenuation and STAT3 silencing, that could potentially inhibit the
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progress of pulmonary fibrosis pathology, and the synthesis and deposition of ECM were
reduced by inhibiting the number of fibroblasts/myofibroblasts.

P-STAT3

DAPI

B

Merged

PFOB/siScr

PFOB/siSTAT3

C

D

DAPI

F

Merged
Merged

1

4
#

0

5.0

**
2.5

##

##

0.0

***

1.5
###

1.0
0.5

thy

##
####

2

0

6

****

4
####

2

####

0

4

x-fold change in
CTGF mRNA

siSTAT3

****

4

H

+PBS

PFOB/siScr

Heal
PFOB/siSTAT3

G

x-fold change in
integrated densuty of α-SMA

α-SMA

DAPI

x-fold change in
integrated densuty of collagen I

Collagen

a-SMA

BLM+PBS

Healthy

Collagen I

BLM

*

0.0

E

BLM+PAMD/BLM+PAMD@ BLM+PAMD@

8

2.0
x-fold change in
STAT3 mRNA

/siSTAT3

BLM+PAMD BLM+PAMD@ BLM+PAMD@

BLM+PBS

Healthy

STAT3

x-fold change in
integrated densuty of P-STAT3

A

x-fold change in
integrated densuty of STAT3

100

2

**

##

0

Healthy
BLM+PBS

BLM+PAMD@PFOB/siSTAT3
BLM+PAMD@PFOB/siScr

BLM+PAMD/siSTAT3

Figure 2.18 Therapeutic activity of EPs in BLM-induced pulmonary fibrosis mice. (A) IF
staining for P-STAT3 and total STAT3. (B&C) Quantitative analysis for total STAT3
expression (B) and P-STAT3 expression (C). (D) STAT3 mRNA expression. (E) IF
staining for collagen I and α-SMA. Quantitative analysis for α-SMA (F) and collagen I (G).
(H) CTGF mRNA expression. Scale bar = 100 μm.

101

4. Conclusion
In summary, we report EPs capable of safe and effective siRNA delivery to the lungs,
which have high mucus penetration and cellular uptake to mediate highly effective
pulmonary STAT3 silencing and CXCR4 attenuation against BLM-induced pulmonary
fibrosis upon intratracheal administration. PFOB EPs with SDF-1 targeting and STAT3
silencing remarkably potentiated the mucus penetration, which happened largely because
of the stabilization of siRNA in the presence of mucus and decreased adsorption of mucus
glycoproteins onto the surface of EPs. Therefore, the emulsion that we developed in this
study can: 1) bind siRNA into EPs, 2) improve the intracellular uptake, 3) penetrate the
mucus layer, and 4) improve pulmonary siRNA delivery and gene silencing efficiency.
Taken together, this may lead to a promising treatment of pulmonary fibrosis via
noninvasive, localized delivery.
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Chapter 3. Nanoemulsion-assisted siRNA delivery to modulate the nervous tumor
microenvironment in the treatment of pancreatic cancer

Please note that this part of the dissertation was published in the ACS Appl Mater
Interfaces (Ling Ding et al, 2022). As the first author, I designed the experiments, collected,
and analyzed the data, and wrote the manuscript. Prof. Oupicky guided me on this project.
Siyuan Tang, et al, helped me with the experiments. All the co-authors agree with including
their work in this dissertation.
1. Introduction
Pancreatic cancer (PC) is one of the most lethal forms of human cancer, with a dismal
five-year survival rate of 8%. PC is also one of the few cancers for which patient survival
rates have remained relatively unchanged since the 1960s [287]. The current best
approach is to effectively diagnose and treat the cancer at an early stage. Unfortunately,
PC is often diagnosed at an advanced stage with metastatic spread observed at diagnosis.
Advanced stages of PC have proven difficult to treat using conventional methods like
surgery and chemotherapy. The available treatment regimens typically only increase
patient medium survival from 5 to 7.2 months [288]. Therefore, there is an urgent need to
develop more effective treatments.
PC is characterized by a complex tumor microenvironment (TME) that plays a key role
in the progression and dissemination. The TME in pancreatic tumors is nutrient-poor,
desmoplastic, and highly innervated. Nervous TME has been suggested to have a crucial
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impact on PC progression and metastasis [289]. Neurons can release stimulatory factors,
such as nerve growth factor (NGF), to accelerate PC tumorigenesis and promote tumor
innervation [290]. In the PC microenvironment, NGF binds tyrosine kinase A (TrkA)
receptors, which leads to the activation of multiple downstream signaling cascades [291],
including the mitogen-activated protein kinase (MAPK)-RAS pathway, then contributes to
the survival, proliferation, and invasion of cancer cells [292]. Another activated pathway in
the PC tumors is the phosphaphatidylinositol 3-kinase (PI3K)-Akt pathway, which supports
survival of both cancer and neuronal cells in the tumors [293]. The expression of NGF in
established PC cell lines and in human pancreatic tumors was reported previously [294,
295]. NGF and its receptors contribute to the survival, proliferation, invasion, and
metastasis of pancreatic cancer cells.[294] Blockade of compensatory neuronal
innervation by LOXO-101, a Trk-NGF inhibitor decreased the PC tumor growth and
suggested that the axonal-cancer metabolic crosstalk is a critical adaptation mechanism
to support PC growth [296]. Moreover, perineural invasion is considered as one of the
factors responsible for the high rate of post-surgical PC recurrence and the pain
associated with PC.
Small interfering RNA (siRNA) is a short double-stranded RNA that can selectively
silence

the

target

gene

expression

with

many

advantages

over

traditional

chemotherapeutics. siRNA-based nanoformulations are a promising strategy for treating
various diseases. Tumor accumulation of nanoformulations is associated with its’
physicochemical properties, such as particle size, zeta potential, and surface modification
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[297].

We

have

developed

perfluorocarbon

(PFC)

nanoemulsions

based

on

perfluorooctylbromide (PFOB) for combined delivery of siRNA and simultaneous inhibition
of C-X-C chemokine receptor type 4 (CXCR4). Polymeric CXCR4 antagonists (PCX)
developed in our lab have been used as stabilizers of the PFOB nanoemulsions and
combined with siRNA to form emulsion polyplexes (EPs) as a new type of multifunctional
soft materials. CXCR4 overexpression is strongly corelated with the poor clinical outcomes
in PC [297, 298]. C-X-C motif chemokine 12 (CXCL12) binds to CXCR4 expressed on the
cancer cells and triggers multiple biological effects, including remodeling of the TME and
promotion of the proliferation, metastasis, and chemoresistance [299]. Blocking of the
CXCL12/CXCR4 axis has been shown promising for treating PC [300].
Due to the immature, compressed tumor blood vessels and the dense extracellular
matrix, conventional intravenous (IV) injection provides limited utility in the treatment of
PC as it leads to the accumulation of low amounts of even small molecule drugs, let alone
nanoparticles, in the tumors. Intraperitoneal (IP) administration emerged as more effective
approach to nanoparticle delivery to PC tumors and peritoneal metastases [297, 301].
Local delivery methods like IP injection can enhance the local drug concentration and
enhance the therapeutic effect [302].
The goal of current study was to investigate the potential of PFOB nanoemulsions as
IP siRNA delivery vectors capable of favorable modulation of the nervous TME (Figure 1).
We selected CXCR4 and NGF as the therapeutic targets because they are both actively
involved in the progression and metastasis of PC. We hypothesized that combining
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Scheme 2. Delivery mechanism of P@P EPs (PCX@PFOB/siNGF) for NGF silencing
and PC therapy. The P@P EPs protects the NGF siRNA from the ascites’ degradation
after the IP injection and enhance the siRNA accumulation to the primary tumors and
metastasis sites. Moreover, the P@P EPs also has the tumor penetration ability, which
will allow the efficient NGF silencing in the tumors. The downregulation of NGF
expression inhibits the PC progression and PNI in pancreatic TME.
knockdown NGF expression with CXCR4 inhibition would enhance the PC therapy via
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high of the tumor penetration and modulation the tumor microenvironments (Figure 1). To
test our hypothesis, the nanoemulsions stabilized with PCX was prepared and complexed
them with siRNA to prepare EPs. We investigated the efficacy of local IP tumor delivery
compared with IV administration and the effect on the therapeutic outcomes in orthotopic
PC model.
2. Materials and Methods
2.1.

Materials
All chemicals were commercially available and used without further purification.

Dulbecco’s modified Eagle medium (DMEM), phosphate buffered saline (PBS), fetal
bovine serum (FBS), trypsin, penicillin and streptomycin were purchased from Thermo
Scientific (Waltham, MA). 1-bromoheptadecafluorooctane (PFOB) were purchased from
Sigma-Aldrich.

NGF

siRNA

(siNGF

CCACAGACAUCAAGGGCAA[91]-3’.

target

siNGF

human,

target

mice,

sense

sequence

5’-

sense

sequence:

5’-

CAGUGUGUGGGUUGGAGAU-3’), negative control siRNA (siNC, sense sequence, 5’UCACAACCUCCUAGAAAGAGUAGA-3’), and Cy5.5 labeled siRNA (Cy5.5-siRNA) were
obtained from Sigma-Aldrich. Average Mw of siRNA is 13300 g/mol. AMD3100 was
brought by Biochempartner (Shanghai, China). Real-time (RT)-PCR primers were
obtained from Sigma-Aldrich. Unless otherwise stated, all other reagents were provided
by Fisher Scientific and used without further purification.
2.2.

Methods

2.2.1. Preparation of PCX@PFOB emulsion polyplexes (P@P EPs)
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PCX and Cy3-PCX were synthesized as described previously [271]. PCX@PFOB
emulsion (P@P emulsion) were prepared as follows. Twenty μL of PFOB was added to 2
mL PCX (2 mg/mL, in water) and ultrasonicated with a probe-type ultrasonic processor
with a 2 mm diameter (Hielscher, UP200ST) with energy limited to 8000 W under 80%
output amplitude setting. P@P EPs was prepared via mixing positively charged P@P
emulsion with siRNA solution in HEPES (pH 7.4) buffer and incubated at room
temperature for 30 min to complete the binding of siRNA onto the P@P emulsion via
electrostatic interaction. siRNA binding to the P@P emulsion was confirmed by agarose
gel electrophoresis. P@P EPs morphology was evaluated using TEM (Tecnai G2 Spirit,
FEI Company, USA) with NanoVan negative staining (Nanoprobes, USA).
P@P E formulated with siNGF are abbreviated as P@P EPs (siNGF), PCX/siNGF
polyplexes are abbreviated as PLX.

P@P E formulated with siNC are abbreviated as

P@P EPs (siNC) and served as control.
2.2.2. Cell culture
Mouse PC tumor cell line KPC8060 was kindly provided by Dr. Hollingsworth at UNMC.
The human PC cell lines COLO357 and PANC-1 was kindly provided by Dr. Batra at
UNMC. All three cell lines were cultured at 37 °C with 5% CO2 in high-glucose DMEM with
10% FBS and penicillin-streptomycin (100 U/mL, 100 μg/mL) in a humidified chamber.
2.2.3. Cell viability assay
Cell viability of P@P EPs was evaluated via CellTiter-Blue (CTB) viability assay. Briefly,
cells were seeded onto 96-well plates, after 18-24 h, cells were treated with 100 μL of
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P@P EPs (w/w = 4, siRNA = 100 nM) in serum-free medium for 4 h. Then, replace with
culture medium and culture for another 48 h. After that, the cell viability was evaluated by
CTB according to the manufacture recommendations. The relative cell viability (%) was
expressed as [F]treated/[F]untreated × 100%. The PBS treated cells were used as 100 % control.
2.2.4. CXCR4 cell surface expression
Cells were cultured under normoxia or hypoxia (0.2% oxygen) for 24 h before
incubation with APC labeled CXCR4 antibody (BD, Bioscience, CA) at 4 °C for 1 h. The
background fluorescence was assessed by isotype-matched antibody. After washing and
centrifugation, cells were analyzed by a flow cytometry and acquired data were analyzed
by FlowJo.
2.2.5. Transwell migration
COLO357 and KPC8060 cells were detached, washed with PBS. The cells were
suspended in 300 μL of serum-free medium, treated with PBS, PCX, P@P E, AMD3100,
and PEI for 15 min before their addition to the cell culture inserts (8.0 μm pores). 600 μL
of serum-free medium containing 20 nM CXCL12 was added into the lower transwell
chamber. After 20 h of incubation, cotton swabs were used to remove the non-migrated
cells in the top chamber. PANC-1 cells were incubated for 24 h in hypoxia before being
subjected to the same transwell migration protocol as COLO357 and KPC8060 cells
above, with the exception of using 40 nM CXCL12 and incubating in hypoxia for 48 h. The
migrated cells at the bottom were fixed and stained with 0.2% Crystal Violet. Migrated
cells were observed under EVOS xl microscope. PEI was used as the negative control.
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2.2.6. Cellular uptake and intracellular trafficking
KPC8060, COLO357, and PANC-1 cells were seeded in 12-well plates. After 18-24 h
of incubation, cells were treated by P@P EPs labeled with FAM-siRNA (w/w = 4, 100 nM
FAM-siRNA). 4 h later, cells were washed with PBS, detached with trypsin, and analyzed
by flow cytometry. Confocal microscopy was used to observe the subcellular distribution
of P@P EPs. Cells were seeded on 8-well chamber, incubated in incubator overnight. The
cells were treated by P@P EPs prepared with Cy3-PCX and Cy5.5-siRNA. After 4 h
incubation, nucleus was stained by Hoechst 33258, and visualized under confocal
microscopy (LSM 800, Zeiss, Germany). To investigate the lysosomal escape, cells were
treated by P@P EPs prepared with Cy3-PCX and Cy5.5-siRNA for 4 h. Then cells were
washed with PBS, stained with LysoView (green), and visualized with confocal microscopy.
To investigate the endocytic uptake mechanism, KPC8060 cells were pretreated with
three inhibitors to inhibit different endocytosis pathways, including Chlopromazine {Cpz,
10 Μm, inhibit clathrin mediated endocytosis (CME) pathway}, Cytochalasin D {CyD, 4
μM, inhibit macropinoctytosis (MP) pathway}, and Nystatin {Nys, 50 μM, inhibit
caveolae/lipid raft dependent endocytosis (C/LR) pathway}. P@P EPs prepared with
FAM-siRNA were used to treat the cells and after 4 h incubation, cells were washed with
PBS, detached with trypsin, and analyzed by flow cytometry and results analyzed by
FlowJo software.
2.2.7. Nanoemulsion penetration in multicellular tumor spheroids
3D tumor spheroids prepared from KPC8060 cells were used to evaluate the
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penetration ability of P@P EPs in vitro. KPC8060 tumor spheroids were prepared by
seeding in 2% agarose attachment 48-well plates (Corning, US) at a density of 1x104 cells
per well and cultured 7 days to allow the spheroids diameter about 300 μm. Then,
KPC8060 spheroids were treated by P@P EPs or PLX prepared with Cy3-PCX and FAMsiRNA for 12 h. After that, the spheroids were washed with PBS and observed under
confocal microscope (z-stack with 10 μm intervals). To investigate the penetration
mechanism of P@P EPs, the spheroids were pretreated by 2-[(4-Fluorobenzoyl)amino]benzoic acid methyl ester (EXO-1) for 1 h, and then incubated with P@P EPs for another
12 h. ImageJ software were used to transform the fluorescence images to surface plots.
Flow cytometry was also used to analyze the penetration ability of P@P EPs by trypsinzing
the spheroids into single cell suspension.
2.2.8. Colony formation
Cells were washed with PBS, detached, and seeded in 12 well plates (KPC8060
200/well, COLO357 600/well, PANC-1 600/well). 24 h later, cells were treated by PLX,
P@P EPs (siNC), and P@P EPs (siNGF) for another 7-10 days. Cells were fixed and
stained with 0.2% Crystal Violet, then washed with PBS three times and photographed.
2.2.9. Apoptosis assay
Cells were seeded in 6 well plates (flow cytometry assay) or 96 well plates (nuclear
staining assay). 24 h later, cells were treated by PLX, P@P EPs (siNC), or P@P EPs for
another 48 h. Cells were trypsinized and stained by fluorescently labeled Annexin V FITC
and propidium iodide (PI) and analysis by FACS. For the nuclear staining assay, cells
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were stained with Hoechst 33258 (2 μg/mL) and photographed under EVOS xl
fluorescence microscopy.
2.2.10. Orthotopic PC model
Animals. C57BL/6 mice (7 weeks old, male) and athymic nude mice (8 weeks old,
male) were obtained from Charles River Laboratories. All animal studies were approved
by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee.
We established orthotopic tumors in athymic nude mice using PANC-1 cells and in
C57BL/6 mice using KPC8060 cells. Mice were anaesthetized before the surgery. Iodine
and alcohol pad were used to get the sterilization of the surgical site. Then, incision at the
left center abdomen region was made, and the pancreas was exposed. 40 μL
Matrigel/PBS (1:1) contained one million of PANC-1 cells or 2.5 x 104 of KPC8060 cells
were injected into the tail of the pancreas. The incision was closed with soft staples. 10
days after surgery, the soft staples were removed.
2.2.11. Blood circulation time
Mice with the KPC8060 orthotopic tumors were given 200 μL of P@P EPs prepared
by Cy3-PCX and Cy5.5-siRNA (w/w = 4, 2.5 mg/kg Cy5.5-siRNA) by IV or IP injection 28
days after tumor implantation. 2 min, 10 min, 1 h, 4 h, and 24 h post-injection, ~80 μL of
blood was collected into heparin-pretreated tubes. 50 μL of blood from each sample was
transferred into plastic tubes and imaged by Xenogen IVIS 200 (Cy3: Ex = 535 nm, Em =
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580 nm, Cy5.5: Ex = 675 nm, Em = 720 nm). The fluorescence intensity was analyzed by
the supplied IVIS software.
2.2.12. Biodistribution of P@P EPs
To study the tumor-targeting ability of P@P EPs, orthotopic KPC8060-derived (28
days after cells implantation) and PANC-1-derived (35 days after cells implantation) PC
models were injected with 200 μL of P@P EPs prepared with Cy3-PCX and Cy5.5-siRNA
(w/w = 4, 2.5 mg/kg Cy5.5-siRNA) by IV or IP. Control animals were given IP injection of
PLX prepared with Cy3-PCX and Cy5.5-siRNA. After 24 h, mice were sacrificed and
imaged with Xenogen IVIS 200. Tumors and major organs were harvested for ex vivo
fluorescence imaging. To investigate the tumor penetration mechanism of the P@P EPs,
mice were pre-injected with EXO-1 (120 μg/mouse) via IP. 1 h later, mice were IP injected
by P@P EPs. After 24 h, tumors were harvested and processed as above. Tumors were
embedded into O.C.T compound, cut into frozen sections (10 μm), and observed by
confocal microscopy.
2.2.13. Antitumor effect in vivo
Twelve days after KPC8060 cell implantation, mice were randomly divided into 4
different groups (n = 5) and IP injected with PBS, PLX (PCX/siNGF), P@P EPs (siNC),
and P@P EPs (siNGF) (w/w = 4, 2.5 mg/kg siNGF). The animals were treated on day 12,
14, 16, 18, 20, 22, 24, and 26. Body weight was monitored during the experiment periods.
Tumor growth was measured by Vevo 3100 ultrasound imaging system (Fujifilm,
VisualSonics, Toronto, ON) in B-mode with an MX550D transducer. Tumor shape and
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volume was analyzed by Vevo Lab software. On day 28, all the mice were sacrificed, and
blood was harvested for analysis. Primary tumors were weighted and metastasis in each
organ was evaluated.
2.2.14. Histological analysis
Tumor tissues were cryo-sectioned and permeabilized with endogenous peroxidase
inhibitor. Tumor slides were incubated with primary antibody at 37 °C for 32 min, including
NGF antibody (Abcam, Ab52918, 1:100), and neurofilament antibody (Abcam, Ab223343,
1:100). After that, the samples were incubated with secondary antibody labeled with FITC.
Tumor slides were also counterstained with DAPI for 10 min at room temperature to
assess the nuclei. The IF staining slides were mounted with antifade reagent and
observed with confocal microscopy (LSM 800). Immunohistochemical staining of PGP 9.5
was performed to evaluate PGP 9.5 tumor expression after treated with P@P EPs.
2.2.15. In vivo toxicity
Histology analysis was used to assess the in vivo toxicity. Major organs, including
heart, liver, spleen, lungs, and kidney, were sectioned, and stained with H&E staining,
then, the slides were observed by EVOS xl microscope.
2.2.16. Statistical analysis.
All results were presented as mean ± SD. One-way ANOVA test with Tukey’s multiple
comparisons test was used to analyze the differences among multiple groups. Student’s
t-test was used to analyze the statistical significance between two groups, and P-value
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<0.05 was considered statistically significant. All statistical analysis was performed with
GraphPad Prism v8.
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3. Results and Discussion
The nervous TME plays an important role during PC progression and metastasis but
remains under-investigated as a target for therapeutic approaches. Here, we set to explore
the possibility of targeting the nervous TME with siRNA therapeutic using novel dually
functioning PFOB nanoemulsions. We have synthesized PCX and formulated P@P
emulsion that maintained the CXCR4 inhibition ability while being able to condense siRNA.
3.1.

Inhibition of cell migration
We have synthesized PCX and formulated PCX@PFOB (P@P) nanoemulsion that

maintain the CXCR4 inhibition ability while being able to condense siRNA. CXCR4
antagonism of P@P emulsion was evaluated by CXCR4 receptor redistribution assay.
Compared with the PCX, the EC50 of the P@P emulsion decreased from 42.7 ng/mL to
28.1 ng/mL.
Considering the improved CXCR4 antagonism of the nanoemulsion, we evaluated its
ability to inhibit migration of murine (KPC8060) and human (COLO357) pancreatic cancer
cells that both express high levels of CXCR4 receptor [297]. Non-cytotoxic concentrations
of P@P emulsion and PCX were used to evaluate the anti-migration activity (Figure 3.1A).
Incubation of the cells with CXCL12 induced their migration, which could be inhibited by
the treatment with P@P emulsions and PCX. There was no difference in anti-migration
activity of P@P and commercial CXCR4 antagonist AMD3100 at the used concentrations.
All the used cell lines, negative control PEI failed to inhibit migration.
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We also evaluated the CXCR4 surface expression in another human PC cell line
PANC-1 cells (Figure 3.1B), but it showed negligible CXCR4 expression in normoxia
condition. However, the expression of CXCR4 in PANC-1 cells greatly increased when
incubating the cells under hypoxia condition (0.2 % oxygen) and we found that 28.9% of
the cells strongly express the receptor (Figure 3.1B). The hypoxia effect on CXCR4
overexpression and the fact that the microenvironment of the solid pancreatic tumors is
highly hypoxic is well established [303]. When we evaluated the ability of the P@P
emulsion to inhibit migration of PANC-1 cells under hypoxia, we observed comparable
results to KPC8060 and COLO357 cells (Figure 3.1A).
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Figure 3.1 (A) Inhibition of CXCL12-induced PC cells migration. KPC8060, COLO357 and
PANC-1 cells were treated with AMD3100 (300 nm), PCX (2 μg/mL), P@P (PCX 2 μg/mL),
PEI (2 μg/mL) and cultured in a transwell membrane insert with CXCL12. Migrated cells
were observed. (B) CXCR4 surface expression in PANC-1 cell surface.
3.2.

Cell uptake and penetration in multicellular spheroids
We used fluorescently labeled P@P/siRNA EPs (P@P EPs, w/w = 4, particle size

~190 nm and zeta potential ~19 mV) to investigate the uptake, intracellular distribution in
KPC8060, COLO357 and PANC-1 cells. As shown in Figure 3.2A, compared with the
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control PEI/siRNA (MW=10k, w/w=2, particle size ~ 145 nm and zeta potential ~ 24 mV)
and PCX/siRNA polyplexes (PLX, w/w = 4, particle size ~ 160 nm and zeta potential ~ 25
mV) without the PFOB emulsion, the uptake of P@P EPs as determined from the mean
fluorescence intensity (MFI) increased 3-fold and 4.8-fold, respectively. The enhanced
siRNA cellular uptake by P@P EPs was also confirmed in the PANC-1 and COLO357 cell
line (Figure 3.2A). the flow cytometry results were corroborated by confocal microscopy
(Figure 3.2B). Both siRNA (yellow) and PCX (red) were observed in the cytoplasm of the
cells, which confirmed effective cellular uptake mediated by the P@P EPs. Endosomal
escape of the P@P EPs in KPC8060 was evaluated by using LysoView (green) to stain
lysosomes. After 4 h incubation, as shown in Figure 3.2C, PCX (red) and siRNA (yellow)
were found mostly in the cytoplasm with only a limited extent of colocalization with the
lysosomes.
In the past decades, various studies have been conducted on the mechanism of
cellular uptake of siRNA therapeutics, however there is no understanding of the
internalization mechanism of systems based on PFC nanoemulsions. Understating of the
siRNA delivery mechanism may help in designing more effective therapeutic strategies.
In this study, the endocytic pathways involved in the uptake of P@P EPs were analyzed
by flow cytometry using a panel of inhibitors that included Cpz, CyD, and Nys [304]. As
shown in Figure 3.2D, the uptake of the P@P EPs was decreased by all three inhibitors
with the strongest effect demonstrated by Nys, where 65% reduction on the uptake was

119

observed. This suggested that the endocytosis mechanism of P@P EPs was mostly
depended on the caveolae pathway.
The intracellular distribution results of P@P EPs in cell monolayers showed that the
cellular uptake of siRNA was improved significantly when compared with PLX. In addition
to cell uptake, poor penetration of siRNA delivery systems into solid tumors is a significant
impediment to their anticancer efficacy. Thus, we moved into the 3D in vitro tumor models
to further determine the penetration ability of the P@P EPs. Penetration of fluorescently
labeled P@P EPs into 3D tumor spheroids was evaluated with confocal microscopy and
flow cytometry. As shown in Figure 3.3B, the P@P EPs exhibited effective tumorpenetrating ability as suggested by the observed internalization in ~66.3% of the cells in
the tumor spheroids. In contrast, only ~15.9% of the cells internalized by PLX. Exocytosis
inhibitor EXO-1 was used to evaluate the penetration mechanism of P@P EPs in the
spheroids. EXO-1 is a reversible inhibitor of exocytosis that induces a rapid collapse of
the Golgi to the endoplasmic reticulum thus inhibiting the traffic emanating from the
endoplasmic reticulum [305]. Only ~16.4% of the positive cells in the tumor spheroids
taken up the EPs when we pretreated them with EXO-1. This result suggested that the
mechanism of the penetration of the P@P EPs was cell-based and dependent on the
exocytosis via the Golgi to endoplasmic reticulum, not on a passive interstitial diffusion.
These results were also confirmed by the confocal microscopy (Figure 3.3A).
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Figure 3.2 (A) The cellular uptake of P@P EPs in KPC8060, COLO357, and PANC-1
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3.3.

Anticancer effect of NGF silencing and CXCR4 inhibition in vitro
The anticancer efficacy of the P@P EPs combining the CXCR4 inhibition with

silencing the NGF gene expression was evaluated in the three PC cell lines (KPC8060,
PANC-1, and COLO357, Figure 3.4A). The cells were treated with P@P EPs, and the
expression of the NGF mRNA was measured by RT-PCR. Treatment with P@P EPs
significantly downregulated the NGF expression in KPC8060 cells (~60% reduction),
PANC-1 cells (~45% reduction) and COLO357 cells (~80% reduction). Then, we
evaluated the anti-cancer activity of the P@P EPs. The P@P EPs prepared with negative
control siRNA (siNC) and PLX (PCX/siNGF) were used as controls. The anti-cancer
activity was evaluated from the inhibition of the colony formation (Figure 3.4B,C) and the
cell viability data (Figure 3.4D). In all three cell lines, the treatment with P@P EPs (siNGF)
showed the highest cell killing activity. We observed 36.9% cell killing in KPC8060, 44.7%
in COLO357, and 36.4% in PANC-1 cells. Moreover, the P@P EPs (siNGF) treatment
strongly inhibited colony formation and growth, with the control groups showing only a
modest inhibitory effect. The cell viability assay evaluates metabolic activity within 2 days,
while the colony formation assay measures tumorigenicity as the capability of a single
cells to form a colony (clonogenicity) lasting ~10 days. NGF is overexpressed in PC tumor
and contribute to the cancer cells survival, proliferation, invasion, and metastasis. As
shown in Figure 3.4B,C, silencing of NGF expression in the PC cells decreased their
clonogenic potential.
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The anticancer results were further validated in PANC-1 cells by measuring apoptosis
(Figure 3.4E,F). More than 60% of the PANC-1 cells were apoptotic after treatment with
the P@P EPs (siNGF). In contrast, P@P EPs (siNC) and PLX groups only showed
negligible induction of apoptosis. We also stained the cells with DAPI and evaluated the
nuclear morphology to count the number of apoptotic cells (Figure 3.4G,H).
NGF/TrkA/p75NTR signaling pathway contributes to the PC cell survival [306, 307].
On the downstream of NGF/TrkA signaling, the NGF-TrkA pathway also triggers the
activation of RAS-MAPK pathway that promotes cancer cell survival and proliferation [306].
Moreover, the binding of SDF-1/CXCR4 can trigger downstream of ligand binding, which
result in many responses, including chemotaxis, cell survival and proliferation. One of the
important functions of chemokine is lymphocyte trafficking. CXCR4 mediated chemotaxis
is mediated by PI3 kinase, which can lead to the activation of the serine-threonine kinase
AKT, which have been evaluated to play a key role in tumor cell survival and possible
proliferation [190]. CXCR4 antagonist can also induces apoptosis by decreasing the
expression levels of the anti-apoptotic protein Bcl-2 and ERK [308]. As shown by our data,
the NGF gene silencing significantly decreased the cancer cell proliferation and enhanced
apoptosis. Overall, P@P EPs that delivered siNGF downregulated the expression of NGF
in both human and murine PC cells, resulting in significant inhibition of the colony
formation and inducing more of the cancer cell apoptosis in vitro. These results confirmed
that combined NGF gene silencing and CXCR4 inhibition by P@P EPs has promising
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anticancer activity even in PC cells alone without the expected effects on the tumor
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3.4.

IP delivery of P@P EPs to orthotopic PC tumors
We established orthotopic PC tumors by injecting the murine KPC8060 and human

PANC-1 cells into the pancreas. These orthotopic PC models mimic the human PC with
similar tumor growth characteristics and oncogene expression, early metastasis, and
strong desmoplastic stroma reaction [309, 310]. Large primary tumors and extensive
metastasis were exhibited in both modes as soon as 4 weeks after cell injection [297].
We first studied how the route of administration affects the pharmacokinetics and
biodistribution of P@P EPs prepared with fluorescently labeled PCX (Cy3) and siRNA
(Cy5.5). The same dose of P@P EPs was given either by IP or IV injection and blood was
collected at selected time points. The fluorescence intensity of Cy5.5-siRNA in the blood
was measured and normalized to fluorescence intensity found 2 min after IV injection
(Figure 3.5A). The siRNA fluorescence intensity in blood was decreased rapidly to ~5.6%
within the first hour after injection, confirming the anticipated rapid clearance of the
positively charged nanoemulsions. When given by IP injection, the blood siRNA
fluorescence intensity reached maximum of ~7.3% at 1 h post-injection, suggesting limited
absorption of the P@P EPs from the peritoneum into blood circulation [311]. This also
suggested that a large portion of the P@P EPs was retained in the peritoneal cavity.
Biodistribution of the P@P EPs was determined 24 h after IP and IV injection. The
fluorescence of whole body and major isolated organs was measured. When given by IV
injection, the P@P EPs mostly accumulated in the liver, spleen, and kidney with negligible
signal seen in the tumor (Figure 3.5). In contrast, the IP injection resulted in strong
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accumulation both in the primary orthotopic tumors and peritoneal metastasis sites.
Importantly, the IP administration significantly decreased the siRNA hepatic and splenic
accumulation. IP injection of nanoformulations involves in different metabolic routes with
faster biliary excretion, have different protein adsorption profiles when compared with IV
injection [312]. To show the role of the PFOB emulsion in the observed biodistribution, we
also determined the biodistribution of the PLX given by IP injection. Although the PLX
showed strong accumulation in the primary tumors, the tumor/liver ratio was significantly
decreased compared with P@P EPs (Figure 3.5F), indicating less effective tumor
targeting, and increased potential for off-target effects.
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3.5.

Intratumoral distribution of P@P EPs
To understand the intratumoral distribution and penetration ability of the P@P EPs,

frozen tumor sections were analyzed by confocal microscopy. Both Cy5.5-siRNA (pink)
and Cy3-PCX (red) fluorescence was observed in the tumors following IP injection (Figure
3.6). Importantly, the fluorescence signal of both active components of the formulation
was found not only on the surface of the tumors facing the peritoneum but also in the inner
regions of the tumors, validating the penetration ability of P@P EPs observed in vitro
(Figure 3.3). Certain PC cell lines can secret factors that recruitment of the fibrogenic cells
to the tumor sites, then generate the fibrotic pancreatic tumor [313]. The orthotopic
KPC8060 tumors have highly fibrotic stroma [297]. A higher stomal content in PC patients
is associated with poor survival outcomes [217]. Interestingly, P@P EPs exhibited
effective tumor penetration even in the presence of the dense fibrotic stroma. In contrast,
the PLX control group showed distribution predominantly on the tumor surface with limited
interior penetration, suggesting a role of the PFOB emulsion in improving the penetration.
As our previously published paper, the cholesterol modification of PCX also could improve
the penetration of PLX. PFOB emulsion are relatively novel kind of soft nanomaterial,
which show great promising in biological application [268, 314]. In contrast to the IP
administration, only very weak Cy5.5-siRNA and Cy3-PCX signals were observed in the
tumors of the mice treated with IV administration. We validated the tumor accumulation
and penetration also in orthotopic PC model using human PANC-1 cells (Figure 3.7).
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Similar to the murine KPC8060 model, effective accumulation and penetration into the
primary tumors and metastatic lesions were observed.
P@P EPs without ascites

P@P EPs with ascites 24 h at 37 °C

2 μm

2 μm

Figure 3.8 Stability of P@P EPs in ascites. TEM observation of nanoparticles after
incubation with ascites 24 h at 37 °C (50% v/v).

Even though there are likely multiple factors involved, the mechanism of high tumor
delivery efficacy of P@P EPs by IP injection is not fully understanding. In the peritoneal
cavity, there are many types of cells and fluids which might be involved in the accumulation
and penetration of the P@P EPs. For the PC delivery, one of the major physical barriers
is the dense stromal desmoplasia [315]. In this study, we demonstrated high tumor and
metastasis accumulation and penetration and limited normal tissue distribution. The
peritoneal retention and protection improve the exposure of the tumors to the higher
concentration as shown by the siRNA protection ability in the ascites (Figure 3.8). Previous
studies showed that the lack of mesothelium on the tumor surfaces contributes to the
tumor localization in peritoneal tumors [297, 311, 316, 317]. In our previous study, we
confirmed that the primary pancreatic tumors and metastasis foci lacked the visceral
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peritoneum composed of the flat mesothelial cells (mesothelium/mesothelial lining) [297].
Compared to the normal tissue, the primary pancreatic tumors and metastasis organs
exhibited the broken mesothelial lining, and lack of the compact mesothelial cells
Even with higher tumor accumulation, successful treatment of solid tumors requires
deep tumor penetration to access all cancer cells. The surface chemical properties of
nanoparticles influence the cellular internalization, endocytosis, and penetration ability
[318]. The core-shell structure of the P@P EPs exhibits unique properties arising from the
combination of PFOB core and PCX shell and geometry. Overall, the IP administration of
P@P emulsion in delivery siRNA is advantageous as it increases the stability of the siRNA
in ascites, avoids the blood circulation of the nanoparticles, and enhances cellular uptake,
tumor penetration and accumulation.
3.6.

Mechanism of tumor penetration of P@P EPs

As hypothesized above, we believe that the observed tumor penetration of the
nanoemulsions is a cell-mediated process. The interactions between P@P EPs and the
tumor cells or other cells like infiltrating macrophages are complex and likely to all
contribute to the delivery efficacy [301]. To evaluate if the penetration mechanism of P@P
EPs in vivo is the same as the one proposed in our in vitro study, we have treated the
tumor-bearing mice with IP injection of EXO-1 prior to administration of the P@P EPs. The
siRNA intensity of the IP injected P@P EPs in the mice pretreated with EXO-1 was
compared with that in mice without EXO-1 (Figure 3.9). We found that pretreatment with
EXO-1 significantly reduced the total siRNA accumulation in the tumor (P = 0.028) and
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most of the siRNA was found in the kidneys. We also found that the siRNA and PCX
fluorescent signals were mostly localized at the tumor periphery in the EXO-1 treated
animals (Figure 3.9C). The tumor accumulation and penetration of P@P EPs was
decreased significantly when we pretreated them with EXO-1, suggesting that exocytosismediated secretion was related to mechanical stimulus (via mechanical stimulus-induced
exocytosis) [319]. However, full understanding of the mechanism of tumor penetration and
potential involvement of other cell types is not completely clear and needs further studies.
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3.7.

Antitumor efficiency and inhibition of PC metastasis by P@P EPs

We evaluated the antitumor effect of the P@P EPs (siNGF) in the orthotopic KPC8060
tumor model (Figure 3.10A). Tumor growth was followed using ultrasound (Figure 3.10B).
The IP injection of P@P EPs (siNGF) remarkably inhibited tumor growth compared with
the P@P EPs (siNC) and PLX according to the ultrasound imaging analysis. Compared
with the untreated group (PBS), treatment with P@P EPs (siNC) exhibited wreaker effect
on the primary tumor growth, suggesting that CXCR4 inhibition alone does not affect tumor
cell proliferation significantly. Treatment with the PLX showed only a small decrease in the
tumor size, likely due to poor tumor penetration ability. Then, the primary pancreatic
tumors were collected for analysis on Day 28 (Figure 3.11A). P@P EPs (siNGF) treated
mice showed the best activity with ~70% inhibition of the primary tumor growth, which
corresponded with ultrasound imaging analysis (Figure 3.10B). The PLX and P@P EPs
control groups only showed ~30% inhibition and 25% inhibition. The antitumor effect of
the CXCR4 inhibition and NGF silencing by the P@P EPs have been improved
significantly, which was due to the higher of the cellular uptake, siRNA transfection and
better tumor penetration. There was no apparent toxicity caused by the different
treatments as demonstrated by the unchanged body weight during the treatment period
(Figure 3.11B).
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Figure 3.10 The antitumor effects of emulsion polyplexes via IP delivery in orthotopic
tumors. (A) Scheme of IP delivery of nanoparticles treatment. KPC8060 cells were
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The metastasis is a common occurrence in PC patients and is a main cause of the
morbidity and mortality of the disease [320]. After we showed the promising efficacy of the
P@P EPs (siNGF) on the primary tumor growth inhibition, anti-metastasis activity was
evaluated (Figure 3.11C). The metastasis in major organs, including liver, spleen, kidney,
intestine, stomach, abdominal wall, and diaphragm were observed in untreated control
(PBS). Treatment with PLX showed slight anti-metastatic effect as indicated by the
reduced number of metastases in the kidney and abdominal wall. The mice treated by
P@P EPs (siNGF) improved the antimetastatic activity even further, displaying complete
inhibition of metastasis to all observed organs and tissues, except for splenic invasion
(Figure 3.11C). Most important is that P@P EPs (siNGF) completely inhibited metastasis
to the liver, which is the main metastasis site in PC. Treatment with P@P EPs (siNC)
showed a weaker effect on the inhibition of PC metastasis. According to our previously
paper, the CXCR4 inhibition by the PCX (PAMD-chol)/siNC exhibited the PC metastasis
inhibition [269]. However, the PCX that we used wasn’t conjugate with cholesterol, this
might be the reason that our result shown that treatment with P@P EPs (siNC) showed a
weaker effect on the inhibition of PC metastasis.
The P@P EPs (siNGF) treated mice showed a significant 45% silencing of the NGF
mRNA expression in the treated tumors (Figure 3.11D). PLX treated mice showed minor
inhibition of the NGF mRNA expression. We also used immunofluorescence staining to
evaluate the effect of the treatment on tumor expression of NGF. The results showed that
P@P EPs (siNGF) treatment induced the greatest inhibition of the expression of NGF
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protein (Figure 3.12A). The enhanced NGF silencing of P@P EPs compared with PLX
was mostly dependent on the enhanced cellular uptake and transfection of nanoparticles,
and the better tumor penetration. Moreover, the P@P EPs induced efficient NGF silencing
without any apparent off-target effects (Figure 3.13), which showed the feasibility of using
P@P emulsion as siRNA carrier for selective siRNA delivery and anti-neurogenic cancer
therapy via IP injection.
To better understand the effect of our treatment on the nervous tumor
microenvironment, we stained neurofilaments (Figure 3.12B). The P@P EPs (siNGF)
treatment significantly reduced the density of intra-tumoral neurites. The quantification
showed that the P@P EPs (siNGF) group reduced ~75% neurite formation in the tumors
compared with PBS group. PLX and P@P EPs (siNC) treatment reduced the intra-tumoral
neurogenesis to a negligible degree. Neurofilament-specific staining of the human
pancreatic tumors suggested that plentiful of neurites within pancreatic tumor tissue
compared with the non-disease pancreas tissues [222]. One of the in vitro studies
suggested that NGF knockdown in the co-culture of PANC-1 cells and dorsal root ganglion
(DRG) neurons induced less DRG neurite sprouting. The NGF depletion with P@P EPs
not only inhibited the primary tumor growth and metastasis but inhibited the intra-tumoral
neurite growth in the PC tumors (Figure 3.10-3.12). The reduced neurogenesis may inhibit
metastasis by the process of perineural invasion. As shown in Figure 8B, the density of
neurites was significantly decreased when treated with the P@P EPs (siNGF). Moreover,
previous study showed that the intratumoral neurogenesis contributed to the progression
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of the pancreatic tumors. Thus, the density of the neurites in the tumor was significantly
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Protein Gene Product 9.5 (PGP 9.5 ), also known as ubiquitin C-terminal hydrolase 1
(UCHL-1), is a nerve fiber marker which has been suggested as a useful prognostic
marker in PC patients due to its relationship to tumor progression [321].
Immunohistochemical staining showed significant decrease of PGP 9.5 expression
following treatment with P@P EPs (siNGF) (Figure 3.12C), indicating efficient inhibition of
tumor nerve fiber formation that may contribute to the observed inhibition of the tumor
growth. Increased content of intratumoral nerve fibers is related to higher metastatic
potential and poorer prognosis [322, 323]. CXCL12/CXCR4 chemotactic pathway also
involved in promoting perineural invasion in PC [324]. CXCL12 promotes the neurite
outgrowth of DRG cells and the stimulating effect can be inhibited by treatment with a
CXCR4 antagonist [325]. When treated by P@P EPs (siNC), the PGP9.5 expression was
also decreased. In the future, we plan to validate these results in additional PC models.
α-SMA is a marker of activated pancreatic stellate cells (PSCs) and fibrosis useful for
evaluating the effect of treatments on PC desmoplasia (Figure 3.12D). Both P@P EPs
(siNC) and PLX reduced the number of activated PSCs in comparison with PBS group.
P@P EPs (siNGF) nanoparticles further inhibited the activation of PSCs significantly. The
activated PSCs can generate the collagen, which is the major component of the tumor
microenvironment. This result confirmed that P@P EPs (siNGF) could inhibit activation of
PSCs and tumor desmoplasia via the combined effect of CXCR4 blockade and NGF
silencing.
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4. Conclusion
In summary, we have demonstrated P@P emulsion as a delivery platform for siRNA
to target the tumor-neuron interaction for pancreatic cancer treatment via NGF silencing
through EPR-independent delivery of nanomedicine using IP administration. P@P EPs
show promising cellular uptake and tumor penetration ability, whereby cellular uptake
depends on the caveolar/lipid raft endocytosis and the tumor penetration depends on the
Golgi/endoplasmic reticulum/exocytosis pathway. P@P EPs provide not only a protective
structure against the ascites in the peritoneal cavity, but also an opportunity for effective
penetration to the tumor sites due to the lack of the mesothelium. P@P EPs exhibited the
best tumor penetration and enhanced NGF gene knockdown in vitro and in vivo, which led
to effective suppression of tumor growth in KPC8060 cells-bearing orthotopic pancreatic
cancer in mice models without adverse effects. All together, P@P emulsion-assisted
delivery of siNGF points to a promising treatment strategy of pancreatic cancer by
improving the tumor penetration and targeting the interactions between the tumor cells
and tumor microenvironment.
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Chapter 4 - Summary and Future Directions
1. Summary
Pulmonary fibrosis is a chronic, progressive-fibrosing interstitial disease where there
is scaring of the lungs, which makes it difficult to breath. It affects ~3 million people
worldwide with incidence increasing dramatically with age.

It is a fatal disease and needs

urgent new treatments. PC is one of the most highly malignant tumors and the 5-year
overall survival rate in patients with PC is lower than 5%, even when treated by the firstline chemotherapeutic drug, gemcitabine. It is necessary to develop methods to treating
pulmonary fibrosis and PC. The CXCR4/CXCL12 axis has significant role in the
fibroblasts-to-myofibroblasts

transformation

and

the

fibrosis

progression,

tumor

progression, angiogenesis, metastasis, and cancer cell-microenvironment interaction.
Studies suggested that inhibition of CXCR4 served as an effective strategy for the
metastasis cancer treatment and pulmonary fibrosis. Various nanomedicines have been
designed based on siRNA. The siRNA nanomedicines gained more attention in regulating
gene expression for treating multiple diseases, including cancer and fibrosis. PFC
nanoemulsion are disperse systems that consisting of nanoscale liquid PFC droplets and
stabilized by an emulsify agent. It is a soft material which can be prepared by highpressure homogenization or microfluidization. PFOB is a linear PFC which is well known
for the biocompatibility and good tolerance for human being. PFOB NPs are
multifunctional nanotechnology. We have synthesized PCX based on AMD3100, a
CXCR4 antagonism. PCX is a dual function polycation which capable of CXCR4 inhibition
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and nucleic acid delivery. In this study, PCX was emulsified with PFOB to form
PCX@PFOB emulsion. Due to the cationic property of this emulsion, it can be used as
the siRNA delivery system to form EPs. Then, we evaluated the therapeutic efficacy of the
EPs for combined therapy in metastasis PC and pulmonary fibrosis. The PCX@PFOB
emulsion can serve as nucleic acid delivery systems. Compared with the commonly used
polyplexes, EPs showed improvement of siRNA cellular uptake and transfection.
Moreover, EPs have better lung penetration, which might be due to the specific properties
of PFOB that can reduce CBF and improve lung penetration. The delivery of siSTAT3 to
the HPLFs resulted in inhibition of the proliferation and migration of fibroblasts, and then
reduced the α-SMA expression and ECM production. The intratracheal delivery of Eps,
combined with CXCR4 inhibition and STAT3 silencing, is a promising strategy for a
combination therapy in pulmonary fibrosis treatment.On the other hand, P@P emulsion
can inhibit the cancer cells migration mediated by CXCL12 due to the CXCR4 antagonism
ability. P@P EPs showed promising cellular uptake and tumor penetration ability, where
the mechanism of cellular uptake was mostly dependent on the C/LR, and the tumor
penetration mechanism was dependent on the Golgi/endoplasmic reticulum/exocytosis
pathway. The NGF depletion with P@P EPs not only inhibited primary tumor growth and
metastasis, but also inhibited the intra-tumoral neurite growth and stromal density in
KPC8060 cell-bearing PC tumor models in vivo. Taken together, P@P emulsion-assisted
delivery of siNGF is a promising treatment approach for PC treatment by targeting the
interaction between the tumor cells and nervous microenvironment.
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2. Future directions
Nanoemulsions dosage form serves as a promising multimodal platform for the
delivery

pharmaceutical

ingredients

and

have

attracted

great

attention

in

pharmacotherapy. In this study, the capacity of the P@P nanoemulsion to delivery
therapeutic nucleic acid and their ability to protect the siRNA mucin and ascites
degradation with good penetration ability.

However, there are still many challenges

before we can consider translating the P@P EPs nanoemulsions to the clinic, even with
the promising potential in mouse models of pulmonary fibrosis and PC, especially due to
poorly controlled colloidal stability. It is necessary that the remaining of the size distribution
after administration. Stability of nanoemulsion should be performed to evaluate the
integrity of the nanoemulsion delivery system, the excipients and the loaded therapeutic
nucleic acid. Hence, clinical translation needs to develop very stable EPs over a long
storage time. Future directions will focus on the development of better of colloidal stability
emulsion by combing with Generally Recognized as Safe (GRAS)-grade excipients, such
as glycerol, soybean oil, disodium edetate and egg lecithin. Even though it is available
that nanoemulsions are easily produced in the industry by using mechanical extrusion
process or high shear stress in large scale, the scale-up and material safety are still
extremely challenging especially when we design the multifunctional nanoemulsion
delivery systems to combine the payload agents (drug or therapeutic nucleic acids) and
targeting ligands. It is necessary that the scale-up and material safety need to be
addressed before being transformed into the clinical application. In this study, the I.P
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injection was used to treating pancreatic tumor mice. However, the translation of I.P
injected nuclear acids formulation into clinic is extremely challenged even with the
promising tumor accumulation by I.P injection in mice models. Hence, we can start with
the I.V administration when moving to clinic. However, the rapid uptake of nanoemulsions
by mononuclear phagocytic system (MPS) also impeded the translation to the clinic when
giving by I.V. injection. In order to preventing the MPS uptake, we can stabilize the
nanoemulsion with PEG, which also can improve the long blood circulation time.
Moreover, in this study, the intratracheal instillation was used for treating mice, we will
use the inhalation in the future. The tumor penetration mechanism was evaluated by using
EXO-1, the exocytosis inhibitors. Future directions will investigate the tumor penetration
mechanism by using more of the other small inhibitors. Moreover, future directions will
focus on the drug delivery using the emulsion that specifically targets lung and tumors.
Moreover, PFOB emulsion can serve as an oxygen delivery system without apparent
toxicity. For example, ICG&PFOB co-loaded nanoliposomes (LIP-PFOB-ICG) showed
promising inhibition of the tumor growth via enhanced PDT&PTT synergistic therapy
because of the excellent oxygen carrying ability of PFOB [326, 327]. Future directions will
also focus on the PTT by formulating different PFOB nanoemulsions.
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